

September 2024

I.- PERSONAL INFORMATION:

NAME: Pablo MENENDEZ BUJAN, PhD, MBA

DATE OF BIRTH November 16th, 1974

NATIONALITY: Spanish

National ID: 10.892.394P

CURRENT POSITION: ICREA Research Professor
Josep Carreras Leukemia Research Institute
Scientific Director - Campus Clinic
Associate Professor. School of Medicine. University of Barcelona. Spain

Chief Scientific Officer
OneChain Immunotherapeutics SL

ADDRESS: Josep Carreras Leukemia Research Institute
School of Medicine - University of Barcelona
Carrer de Casanova 143. 08036. Barcelona. Spain

TELEPHONE: Mobile: + 34 655 010572

E-mail: pmenendez@carrerasresearch.org

II.- PROFESSIONAL KEYWORDS:

- Acute lymphoblastic and myeloid leukemia.
- MLL rearrangements and aneuploidy.
- Immunotherapy – CAR T Cells.
- Inflammation and stromal cells.
- Stem cells (hematopoietic, mesenchymal, and pluripotent).
- iPSC-based disease modelling.
- Gene editing and gene therapy.

III.- EDUCATION:**-Scientific:**

- 04/2002 Ph.D. (Department of Medicine) University of Salamanca. Spain.
 Thesis Dissertation: Enumeration and immunophenotypic characterization of CD34+ HSC from bone marrow and mobilised peripheral blood: clinical impact on autologous and allogeneic peripheral blood transplantation.
 Supervised by Prof. Alberto Orfao & Jesus San-Miguel
 Thesis qualification: *Cum laude*
- 09/1997 B. Sc. (Biochemistry and Molecular Biology) University of Salamanca. Spain.

-Management:

- 11/2021 Tech Transfer Leadership in Life Sciences. Barcelona School of Management. La Caixa Validate Impulse Program. Spain.
- 07/2018 PADIIT, Master in Management of Health, innovation and transfer technology. IESE Business School. Universidad de Navarra, Spain.
- 05/2016 Leadership & Coaching Master. IE Business School. Madrid. Spain.
- 06/2010 Full (18 months) Executive MBA. IIST Business School. Spain.

IV.- TRAINING AND PREVIOUS APPOINTMENTS:

- 04/2015-present Associate Professor. School of Medicine. University of Barcelona.
- 07/2013-present ICREA Professor. Principal Senior Investigator. Josep Carreras Leukemia Research Institute. University of Barcelona University.
 IJC Campus Clinic Coordinator.
- 09/2011-06/2013 Principal Investigator. GENyO (Centre Pfizer-University of Granada-Andalusian Government for Genomics & Oncology). Granada. Spain.
- 11/2006-09/2011 Director of the Andalusian Stem Cell Bank. Granada. Spain
- 10/2005-11/2006 Josep Carreras Trust Fellow. Section of Hemato-Oncology headed by Prof. Mel Greaves. Institute of Cancer Research, London, UK.
- 08/2002-10/2005 Canadian Institutes of Health Research (CIHR) post-doctoral fellow in Dr. Mick Bhatia's Lab. Stem Cell Biology. Robarts Research Institute, University of Western Ontario, London, ON, Canada.
- 04/2002-07/2002 Post-doctoral fellow in Hematology and Immunopathology, Department of Medicine, University of Salamanca, Spain.
- 09/1997-04/2002 Ph.D. student, Laboratory of Hematology and Immunopathology, Department of Medicine, University of Salamanca, Spain.
- 09/1996-05/1997 Final year student, Laboratory of Hematology and Immunopathology, Department of Medicine, University of Salamanca, Spain.

V.- AWARDS, FELLOWSHIPS AND PROFESSIONAL APPOINTMENTS:

2023	II Joan Roget Award on knowledge and technology transfer (by Catalan Government)
2023	XXVIII Award Rafael Hervada (Fundación San Rafael) on cancer immunotherapy.
2023	ERC Transition grant by European Innovation Commission.
2022	ERC Proof-of-Concept Grant by the European Research Commission.
2020	ERC Proof-of-Concept Grant by the European Research Commission.
2020	Best CIBERONC Young Researcher 2020
2019	Corverano Ejemplar 2019. Award granted by the county of Corvera (my birth county).
2019	Ramiro Carregal 2019 Award for Spanish emerging talent in oncology research.
2018	ERC Proof-of-Concept Grant by the European Research Commission.
2015	ERC Consolidator Grant by the European Research Commission.
2013	ICREA Research Professor. Government of Catalunya. Spain.
2010	Award “Conde de Cartagena” promoted by The Real Academia Nacional de Medicina for the scientific contributions to the etiology and pathogenesis of the infant B-ALL.
2008	Award “Tercer Milenio” to under 35 Young Outstanding Investigator. Promoted and funded by The Innovation, Science and Enterprise Andalusian Government.
2007	Director Andalusian Stem Cell Bank, Sub-director Spanish National Stem Cell Bank.
2006	Tenure Principal Investigator. Regenerative Medicine & Cell Therapy. ISCIII. Madrid.
2005	International Foundation Jose Carreras /E.D.Thomas Fellowship.
2004	Ramon y Cajal Fellowship (Spanish Ministry of Science and Technology). Area of Medicine. Declined in favour of Jose Carreras Fellowship in London, UK.
2004	Canadian Institutes of Health Research (CIHR) postdoctoral Fellowship.
2003	International Stem Cell Conference Travel Award. Singapore. October.
2002	Robarts Research-UWO Fellowship.
1998	Graduate Ph.D. scholarship, Health Ministry of Spain (FIS scholarship).
1998	DAKO studentship

VI.- TEACHING:

2006-present.	Supervision of >40 PhD students, postdocs and technical staff.
2014-present	Master of Biomedicine. University of Barcelona. Spain.
2014-present	Degrees of Biotechnology and Biomedicine. University of Barcelona. Spain.
2012-present	Invited Professor. Master of Molecular Oncology. University of Oviedo. Spain.
2013-2014	Invited Professor. Master of Molecular Oncology. CNIO. Madrid. Spain.
2008-2013	Invited Professor. Master of Regenerative Medicine. University of Granada. Spain.
2011-2012	Invited Lecturer. EMBO & EuroStemCell Consortium for High School Teachers.

VII.-BENCH-TO-BEDSIDE CLINICAL ACHIEVEMENTS

Asset OCI-001 - CD1a-directed CARTs for refractory/relapsed CD1+ cortical T-ALL
Developed and patented in by our Lab (Sanchez-Martinez, Blood 2019; patent ref. WO2020/165350).
Licensed to OneChain ImmuneTx.
Designation Orphan Drug by European Medicines Agency (EMA). EMA/OD/0000062804 (5th,11,2021).
Designation Orphan Drug by Food and Drug Administration (FDA). FDA/DRU-2023-9582 (5th,11,2023).
Phase I clinical trial: Registration Number: EudraCT 2021-002333-42.

VIII.-COMPETITIVE SCIENTIFIC GRANTS:

AECC – Proyectos generales 2023

Amount: 300.000€

Period: 2023-2026

Project: CD1a/CCR9-directed “next generation” allogenic adoptive immunotherapy for T-ALL

PI: **Pablo Menendez**

MINECO RETOS COLABORACION (CPP2022-009759)

Amount for PM’s Lab: 341.000€

Period: 2023-2026

Project: Desarrollo de una terapia CAR dual dirigida para el tratamiento de la T-ALL en recaída.

PI: Jorge Alemany (OCI), **Pablo Menendez** (IJC), Sergi Querol (BST).

MINECO PID2022-142966OB-100

Amount: 462.000€

Period: 2023-2026

Project: Chromosome instability and leukemia-initiating stem cell-driven pathophysiology of aneuploid childhood B-cell acute lymphoblastic leukemia.

PI: **Pablo Menendez & Oscar Molina**

EUROPEAN INNOVATION COUNCIL (HORIZON-EIC-2022-TRANSITION-01 - 101113067)

Amount: 2.500.000€

Amount for PM’s Lab: 120.000€

Period: 2022-2024

Project: A CCR9/CD1a-directed tandem CAR therapy for R/R T-ALL

PI: OneChain ImmunoTx SL, **Pablo Menendez** (IJC), María Luisa Toríbio (CBMSO-CSIC).

AGAUR - GRUPOS SGR-Cat 2021 (2021 SGR 00887)

Amount for PM’s Lab: 60.000€

Period: 2022-2024

Project: Stem cell biology, developmental leukemia and immunotherapy

PI: **Pablo Menendez** (IJC)

MINECO LINEAS ESTRATEGICAS

Amount for PM’s Lab: 398.000€

Period: 2023-2025

Project: Innovative immunotherapies for Ewing Sarcoma

PI: **Pablo Menendez** (IJC), Angel Montero (HSJD), Enrique de Álava (HUVR-IBiS)

MINECO RETOS COLABORACION (CPP21-008676)

Amount for PM’s Lab: 203.000€

Period: 2022-2024

Project: FICAT, development of a genetic engineering technology applicable to CAR T cell therapies.

PI: Integra Tx SL, **Pablo Menendez** (IJC), Marc Guell (UPF).

MINECO RETOS COLABORACION (CPP21-008508)

Amount for PM's Lab: 232.225€

Period: 2023-2025

Project: Phase I clinical trial with autologous CD1a-directed CAR T cells for cortical T-ALL patients.

PI: Onechain Tx SL, **Pablo Menendez** (IJC), Susana Rives (HSJD).

ERC-PoC 2022 – 101100665

Amount: 150.000€

Period: 2023-2024

Project: CD22/CD19 dual redirection of T-cells simultaneously secreting BiTEs and expressing CARs for advanced B-cell Acute Lymphoblastic Leukemia.

PI: **Pablo Menendez**

European Science Foundation (EFS) – Fight Kids Cancer 2022

Amount: 492.000€. Amount P.M's lab: 25.000€.

Period: 2023-2025

Project: Cure4MLL pediatric B-ALL

PI: **RW Stam, G Cazzaniga, Tom Milne, A Roy, K Ottersbach, M Parra, Pablo Menendez**

MERCK

Amount: 30.000€

Period: 2022-2023

Project: Tailored adoptive cellular immunotherapy for Ewing Sarcoma

PI: **Diego Sánchez-Martínez & Pablo Menendez**

HORIZON EUROPE – CANCERNA (Ref.101057250)

Amount: 6.000.000€ - 350.500 for PM's Lab.

Period: 2022-2024

Project: RNA-processing for anti-cancer immunotherapy

Coordinators: Lotem Michal (Israel) & Rotem Karni (Israel) - PI: **Pablo Menendez**

RICORS – TERAIV, ISCIII.

Amount: 160.000€

Period: 2022-2024

Project: Red Española de Terapias Celulares Avanzadas

PI: **Pablo Menendez & Josep María Ribera**

Caixa Impulse Validate

Amount: 100.000€

Period: 2022-2023

Project: Tailored adoptive cellular immunotherapy for Ewing Sarcoma

PI: **Pablo Menendez & Enrique de Alava**

Spanish Association for Cancer Research

Amount: 300.000€

Period: 2022-2024

Project: Next Generation Universal T-cell Redirected ImmunoTherapy for Pediatric Acute Leukemia

PI: **Clara Bueno and Pablo Menendez**

Josep Carreras Leukamie Stiftung DJCLS 15R/2021

Amount: 137.000€

Period: 2022-2024

Project: Acute Myeloid Leukemia initiating cells: Contribution of hypoxia/HIF pathway to chemoresistance and relapse

PI: **Irmela Jeremias (Munich), Talía Velasco-Hernandez & Pablo Menendez**

MINECO SAF-2019-108160-R

Amount: 280.000€

Period: 2020-2023

Project: TIM3, una nueva y prometedora diana inmunoterapéutica en leucemia linfoblástica aguda B de novo y en recaída (TIMBALL)

PI: **Pablo Menendez**

ERC-PoC 2020 - 957466

Amount: 150.000€

Period: 2020-2022

Project: Clinical translation of a novel CD1a-directed CAR for relapse/refractory cortical T-cell Acute Lymphoblastic Leukemia: feasibility, efficacy and safety

PI: **Pablo Menendez**

INTERREG POCFETA - EFA360/19

Amount: 100.000€

Period: 2020-2022

Project: PROTEOblood – PDX models for protein discovery in lymphoma and AML.

PI: **Gael Roue (coordinator) - Pablo Menendez (co-IP)**

German Josep Carreras Leukamie Stiftung

Amount: 118.000€

Period: 2020-2022

Project: Healthy Versus Non-Healthy Aging: Identifying Metabolic and Epigenetic Vulnerabilities of Single Leukemic Stem Cells in Acute Myeloid Leukemia Patients

PI: **Nina Cabezas-Wallshield (Freiburg) & Pablo Menendez**

La Caixa Health Research Program 2019

Amount: 500.000€

Period: 2020-2022

Project: Next-generation CAR-DOT cells for allogeneic adoptive cancer immunotherapy in AML

PI: **Bruno Silva-Santos (iMM-Lisbon) and Pablo Menendez (IJC)**

AECC-Semilla

Amount: 20.000€

Period: 2019-2020

Project: Redirecting CAR T-cells to the BM: improved CAR T-cell persistence and anti-leukemia effects while alleviating related toxicities

PI: **Pablo Menendez (IJC)**

Fundación Uno entre Cienmil

Amount: 100.000€

Period: 2019-2021

Project: Towards a clinical translation of the CD1a-directed CAR for relapse/refractory cortical T-cell Acute Lymphoblastic Leukemia and Langerhans Cell Histiocytosis: feasibility, efficacy and safety.

PI: **Pablo Menendez (IJC)**

Banco Santander. Ayudas a proyectos sociales

Amount: 40.000€

Period: 2019-2020

Project: Infant Leukemia: lessons from monozygotic twins.

PI: **Pablo Menendez (IJC)**

Fundación Leo Messi

Amount: 282.000€

Period: 2019-2021

Project: Epigenetics in infant Leukemia.

PI: **Pablo Menendez (IJC)**

European Food and Safety Authority. Ref. EFSA.PRAS.2018.04-CT1

Amount: 50.000€

Period: 2019-2020

Project: Genotoxic impact of permithrine & chlorpyrifos in human stem cells and leukemia development.

PI: **Pablo Menendez (IJC)**

Health Cooperative Translational H2020 (CLOSER)

Amount project: 4 Mill €, Amount PM's Lab: 120.000€

Period: 2019-2022

Project: **CLOSER: Childhood Leukaemia: Overcoming distance between South America and Europe Regions.**

Coordinator: **Mireia Camos (HSJD, Barcelona)**

PI: **Pablo Menendez (IJC)**, Anthony Moorman (UK), Peter Trka (Czech Republic), Oscar Hass (Austria), Marisa Felice (Argentina), Myriam Campbell (Chile), Luis Castillo (Uruguay).

MINECO RETOS COLABORACION (RTC-2018-4603-1)

Amount: 282.000€

Period: 2018-2021

Project: Obtención de hematíes in vitro generados desde iPSC de donantes con fenotipos eritrocitarios seleccionados y modificados por edición génica como alternativa a los paneles diagnósticos actuales.

PI: **Pablo Menendez (IJC) & Nuria Nogues (BST)**

European Research Council. ERC Proof-of-concept. ERC-PoC-2019-811220

Amount: 150.000€

Period: 2018-2020

Project: Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia

PI: **Pablo Menendez**

AGAUR-Generalitat de Catalunya

Amount: 62.000€

Period: 2018-2019

Project: Grupo SGR330 (Support Grupo Recerca)

PI: **Pablo Menendez**

Beca FERO. Fundación FERO

Total Amount: 70.000€

Period: 2017-2018

Project: Inmunoterapia adoptiva con CAR-NG2 T cells para leukemia linfoblástica y mieloblástica aguda con reordenamiento de MLL.

PI: **Clara Bueno** and **Pablo Menendez**.

PROJECTES RECERCA I INNOVACIÓ EN SALUT (PERIS). GENERALITAT CATALUNYA

Total Amount: 960.000€

Amount for P.M group: 260.000€

Period: 2017-2019

Project: Blood regeneration from human pluripotent stem cells

PI: **Anna Bigas** (IMIM) and **Pablo Menendez** (IJC).

MINECO RETOS (SAF-2016-80481-R)

Amount: 324.000€

Period: 2017-2019

Project: Inmunoterapia adoptiva con CAR-NG2 T cells para leukemia linfoblástica y mieloblástica aguda con reordenamiento de MLL.

PI: **Pablo Menendez** (IJC).

MINECO RETOS COLABORACION (RTC-2016-4603-1)

Amount: 123.000€

Period: 2016-2018

Project: Escalado del suministro y estudios de eficacia del indolocarbazol EC-70124 en modelos animales predictivos. (INDOLKIN)

PI: Francisco Moris (Entrechem SL), **Pablo Menendez** (IJC), René Rodríguez (FINBA).

Foundation INOCENTE INOCENTE 2015

Amount: 30.000€

Period: 2015-2016

Project: Secondary oncogenic events and leukemia-initiating cell in MLL-AF4+ infant acute lymphoblastic leukemia

PI: **Pablo Menendez**

Fundraising PRECIPITA 2015

Amount: 11.000€

Period: 2015-2016
Project: Understanding infant leukemia
PI: **Pablo Menendez**

ERC Consolidator Grant 2014. ERC-CoG-2014-646903

Amount: 2.000.000€
Period: 2016-2020
Project: Genomic, cellular and developmental reconstruction of pediatric MLL-AF4+ Acute Lymphoblastic Leukemia.
PI: **Pablo Menendez**

HEALTH CANADA H4080-144541

Amount: 340.000€
Period: 2014-2019
Project: Pro-inflammatory bone marrow stroma in Acute Myeloid Leukemia: implication in the onset, evolution and drug resistance.
PI: **Pablo Menendez & Michael Rosu-Myles (Ottawa)**

Celgene S.L

Amount: 38.000€
Period: 2014-2016
Project: DOT1L and MLL infant leukemias
PI: **Pablo Menendez**

German Josep Carreras Leukamie Stiftung

Amount: 116.000€
Period: 2015-2016
Project: Embryonic or fetal origin of the target cell for MLL-AF4 transformation in infant acute lymphoblastic leukemia.
PI: **Pablo Menendez & Rolf Marschalek (Frankfurt)**

AGAUR-Generalitat de Catalunya

Amount: 44.000€
Period: 2014-2016
Project: Grupo SGR330 (Support Grupo Recerca)
PI: **Pablo Menendez**

Plan Nacional 2013-MINECO (SAF2013-43065)

Amount: 300.000€
Period: 2014-2016
Project: Célula Diana y eventos oncogénicos secundarios en la leucemia linfoblástica aguda del lactante con reordenamiento MLL-AF4+.
PI: **Pablo Menendez, Alejandra Sanjuan, Julio Castaño, Angélica Horrillo.**

Fundación Sandra Ibarra para cáncer infantil 2013

Amount: 12.500€
Period: 2014

Project: Leucemia Linfoblástica aguda pro-B del lactante: eventos oncogénicos secundarios en la transformación por el oncogén MLL-AF4 en un modelo humano basado en progenitores hematopoyéticos CD34+ de cordón umbilical

PI: **Pablo Menendez**

Career Integration Grant (CIG) European Commission

Amount: 100.000€

Period: 2014-2017

Project: Cell of origin and secondary oncogenic events in MLL-AF4+ pro-B Acute Lymphoblastic Leukemia.

PI: **Pablo Menendez** & Alejandra Sanjuan

E-Rare-2 Call 2012 / EU 7FP Ref. PI12/03112

Amount: 135.000€

Period: 2013-2015

Project: Coenzyme Q₁₀ deficiency syndrome: understanding the genotype-phenotype association and metabolic dysfunction through generation of induced pluripotent stem cells (iPSC) from patient-specific uncorrected and genetically-corrected cells.

PI: **Pablo Menendez (IP-Coordinator)**, Jacob Hanna (Weizmann) & Audrey Carriere-Pazat (Inserm)

Health Canada. Ref. H4084-112281

Amount: 154.000€

Period: 2011-2013

Project: Genomic analysis of mesenchymal stem cells to develop high throughput diagnostics for measuring the medicinal ingredient and tumourigenic contaminants in stem cell-based health products.

PI: Michael Rosu-Myles & **Pablo Menendez**

Asociación Española Contra el Cáncer (AECC) 2011. Ref: CI110023MENE

Amount: 150.000€

Period: 2011-2013

Project: Infant MLL-AF4+ pro-B Acute Lymphoblastic Leukemia: towards the elucidation of the cellular and molecular mechanisms underlying MLL-AF4 transformation in human stem cells

PI: **Pablo Menéndez**

Innovation & Science Department. Andalusian Government.

Amount: 168.000€

Period: 2011-2014

Project: Implication of the haematopoietic transcription factors RunX1 and SCL in blood differentiation from hESCs

PI: Pedro. J. Real & **Pablo Menendez**

Spanish Ministry of Health (FIS) Ref: PI10/00449

Amount: 200.860€.

Period: 2011-2013

Project: Development of new cellular and molecular strategies for the generation of fully functional hematopoietic and mesenchymal stem cells from human ESCs and iPS cells.

PI: **Pablo Menendez**

Science, Innovation & Technology Spanish Ministry (MICINN). Ref: PLE2009-0111

Amount: 347.000€.

Period: 2010-2012

Project: Towards the generation of hematopoietic stem cells from hESC: lessons from the mouse.

PI: **Pablo Menendez**

Innovation & Science Department. Andalusian Government. Ref: P08-CTS-3678.

Amount: 213.600€.

Period: 2009-2012

Project: Stem Cells and Cancer: Molecular and cellular mechanisms underlying pediatric mesenchymal cancer (leukemias and sarcomas).

PI: **Pablo Menendez**

Andalusian Health Department. Ref: 0030/08

Amount: 177.000€

Period: 2009-2011

Project: Mitochondrial Function and Genetics in the biology of human ESCs.

PI: Miguel Martín & **Pablo Menendez (Co-Applicant)**

Spanish Ministry of Health (FIS) Ref: PI070026

Amount: 80.000€.

Period: 2007-2009

Project: Development of a model for acute lymphoblastic leukemia pro-B MLL-AF4+ based on the use of human embryonic stem cells and umbilical cord blood.

PI: **Pablo Menendez**

Andalusian Health Department. Ref: 0030/06

Amount: 165.500€

Period 2007-2008.

Project: Development of feeder-free culture conditions for imported and newly derived human embryonic stem cells (hESC): Generation of NOD/SCID hematopoietic repopulating cells from these hESC lines by expressing HOXA9 alone or in co-culture with CB-derived mesenchymal stem cells.

PI: **Pablo Menendez**

Andalusian Health Department. Ref: 0028/06

Amount: 161.500€

Period 2007-2008.

Project: Pre-hematopoietic origin of the pediatric-associated chromosomal translocations MLL-AF4, TEL-AML 1 and HIPERDIPLOIDY: Development of an In Vitro and In Vivo Model for Cellular Transformation based on the use of human adult mesenchymal stem cells.

PI: **Pablo Menendez**

Andalusian Health Department. Ref: 0029/06

Amount: 170.500€

Period 2007-2008.

Project: Developmental Impact of MLL-AF4 Leukemic Fusion Gene on Human Stem Cell Fate

PI: **Pablo Menendez**

Leukaemia Research Fund. Ref.06039

Amount: 154.689 GBP£

Period: 08/2006-08/2008

Project: Modelling MLL fusion gene leukomogenesis in human stem cells

PI: **Pablo Menendez** and Mel Greaves

IX.- HUMAN RESOURCES:

Maria Skłodowska-Curie Fellowship Grant – EU proposal 951078308

Period: 2025-2027

Project: Targeting non-Hodgkin B-cell lymphoma with a novel CAR T cell therapy.

Fellow: **Klaudyna Fidył**

Supervisor: **Pablo Menéndez**

PhD scholarship – FPI 2024

Period: 2024-2027

Project: Chromosome instability and leukemia-initiating stem cell-driven pathophysiology of aneuploid childhood B-cell acute lymphoblastic leukemia.

Fellow: **Cristina Calvo**

Supervisor: **Pablo Menéndez, Oscar Molina**

Investigador postdoctoral Juan de la Cierva

Period: 2023-2024

Project: Allogenic adoptive cell therapy for hematological malignancies

Fellow: **Aida Falgàs**

Supervisor: **Pablo Menéndez**

Investigador AECC.

Period: 2023-2026

Project: Acute Myeloid Leukemia initiating cells: Contribution of hypoxia/HIF pathway to chemoresistance and relapse

Fellow: **Talía Velasco-Hernández**

Supervisor: **Pablo Menéndez, Jordi Sierra**

Maria Skłodowska-Curie Fellowship Grant – EU proposal 951078308

Period: 2018-2020

Project: Contribution of lipid droplets to the pathogenesis and chemoresistance of AML

Fellow: **Remi Safi**

Supervisor: **Pablo Menéndez / Albert Pol**

Lady Tata International Foundation 2022

Period: 2022-2023

Project: Contribution of lipid droplets to the pathogenesis and chemoresistance of AML

Fellow: **Remi Safi**

Supervisor: **Pablo Menéndez**

PhD scholarship – PFIS, ISCIII

Period: 2022-2025

Project: Tailored adoptive immunotherapy for Ewing Sarcoma

Fellow: **Carla Panisello**

Supervisor: **Pablo Menéndez, Clara Bueno**

Investigador AECC.

Period: 2022-2025

Project: Contribution of chromosome instability to the outcome of aneuploid childhood B-cell acute lymphoblastic leukemia.

Fellow: **Oscar Molina Campoy**

Supervisor: **Pablo Menéndez**

Juan de la Cierva. Postdoctoral fellowships

Period: 2020-2022

Project: Computational single cell analysis in immune-oncology

Fellow: **Juan Luis Trincado**

Supervisor: **Pablo Menéndez**

PhD scholarship – FPI 2021

Period: 2021-2015

Project: Pathogenic contribution of chromosomal damage and CIN in aneuploid childhood ALL

Fellow: **Namitha Tampi**

Supervisor: **Pablo Menéndez**

PhD scholarship – FI AGAUR 2020

Period: 2020-2024

Project: Allogenic adoptive cell therapy for hematological malignancies

Fellow: **Nestor Tirado**

Supervisor: **Pablo Menéndez**

Sara Borell. Postdoctoral fellowships

Period: 2020-2022

Project: Immunotherapy for hematological malignancies

Fellow: **Diego Sánchez-Martínez**

Supervisor: **Pablo Menéndez**

Lady Tata UK Fund. Postdoctoral fellowships

Period: 2019

Project: Bi-specific CARs for B-cell ALL

Fellow: **Belén López-Millán**

Supervisor: **Pablo Menéndez**

Juan de la Cierva. Postdoctoral fellowships

Period: 2018-2020

Project: Gene editing in human primary cells

Fellow: **Meritxell Vinyoles**
Supervisor: **Pablo Menéndez**

Maria Skłodowska-Curie Fellowship Grant – EU proposal 795833

Period: 2018-2020
Project: Innovative Therapies for MLLr B-ALL
Fellow: **Samanta Zanetti**
Supervisor: **Pablo Menéndez**

Maria Skłodowska-Curie Fellowship Grant – EU proposal 792923

Period: 2018-2020
Project: Contribution of HIF pathway to AML-Leukemia Initiating Cells
Fellow: **Talía Velasco**
Supervisor: **Pablo Menéndez**

Beatriu de Pinos-Generalitat de Catalunya. Postdoctoral fellowships

Period: 2018-2020
Project: Chromosome segregation and centromere defects in hyperdiploid BCP-ALL
Fellow: **Oscar Molina**
Supervisor: **Pablo Menéndez**

Lady Tata UK Fund. Postdoctoral fellowships

Period: 2017
Project: Chromosome segregation and centromere defects in hyperdiploid BCP-ALL
Fellow: **Oscar Molina**
Supervisor: **Pablo Menéndez**

AECC. Postdoctoral fellowships

Period: 2018-2021
Project: Genome editing for generation of chromosomal translocations in CD34+ cells.
Fellow: **Raúl Torres**
Supervisor: **Pablo Menéndez**

Lady Tata UK Fund. Postdoctoral fellowships

Period: 2017
Project: Genome editing for generation of chromosomal translocations in CD34+ cells.
Fellow: **Raúl Torres**
Supervisor: **Pablo Menéndez**

Juan de la Cierva. Postdoctoral fellowships

Period: 2017-2018
Project: Chemical exposure to household pesticides and MLL rearrangements in human stem cells
Fellow: **Virginia Rodríguez**
Supervisor: **Pablo Menéndez**

MINECO. Programa Técnicos de Apoyo 2015

Period: 2015-2017

Project: Responsible of animal facility and experimentation.

Fellow: **Silvia Cufi**

Supervisor: **Pablo Menéndez**

MINECO. Contrato Ramón y Cajal

Period: 2015-2019

Project: GATA2 in primitive and definitive hematopoiesis from human pluripotent stem cells.

Fellow: **Alessandra Giorgetti**

Supervisor: **Pablo Menéndez**

Generalitat de Catalunya. Programa Beatriu de Pinos

Period: 2014-2016

Project: Cell of origin and secondary oncogenic events in MLL-AF4+ pro-B ALL.

Fellow: **Alejandra Sanjuan-Plá**

Supervisor: **Pablo Menéndez**

MINECO. Contrato Juan de la Cierva

Period: 2013-2015

Project: Secondary oncogenic events in infant MLL-AF4+ Acute Lymphoblastic Leukemia

Fellow: **Rosa M^a Montes Lorenzo**

Supervisor: **Pablo Menéndez**

Fondo Investigaciones Sanitarias. Contrato Miguel Servet 2012

Period: 2013-2018

Project: Modelling MLL-AF4+ and TEL-AML1+ pro-B and pre-B childhood Acute Lymphoblastic Leukemias using patient-specific iPSCs

Fellow: **Verónica Ramos Mejía**

Supervisor: **Pablo Menéndez**

Fondo Investigaciones Sanitarias. Contrato Miguel Servet 2009

Period: 2010-2015

Project: Role of SCL and RunX1 transcription factors in hematopoietic differentiation from hESCs.

Fellow: **Pedro J. Real**

Supervisor: **Pablo Menéndez**

Fondo Investigaciones Sanitarias. Contrato Miguel Servet 2008 CP07/00059

Period: 2008-2013

Project: Developmental impact of MLLAF4 oncogene linked to infant ALL on Human Stem Cell Fate

Fellow: **Clara Bueno Uroz**

Supervisor: **Pablo Menéndez**

Marie Curie International Incoming Fellowship. FP7-PEOPLE-IIF-2008

Period: 2009-2011

Project: Developmental impact of MLLAF4 oncogene linked to infant ALL on Human Stem Cell Fate

Fellow: **Verónica Ramos-Mejía**

Supervisor: **Pablo Menéndez**

Asociación Española Contra el Cáncer. AECC 2009

Period: 2009-2011

Project: Células madre y cáncer: un modelo de liposarcoma basado en la instrucción del encogen FUS-DDIT3 en células madre mesenquimales

Fellow: **René Rodríguez González**

Supervisor: **Pablo Menéndez**

Fondo Investigaciones Sanitarias. Contrato Sara Borrell 2008

Period: 2008-2012

Project: El papel de la ruta Notch en la autorrenovación y diferenciación de células madre hematopoyéticas.

Fellow: **Pedro J. Real**

Supervisor: **Pablo Menéndez**

X.- CAPITAL MONEY:

Infrastructure Call: ISCIII-2006 412.000€ Period: 2007

Equipment: 1.- Microarrays Platform (Agilent).
2.- AUTOMacs Cell Isolator (Miltenyi).
3.- FACSCanto High-Speed Flow Cytometry Analyser (BDB)
4.- ACUDU, Temperature Controller and flow cytometry workstation (DBD).

Applicants(s): **Pablo Menendez** for BACM

Infrastructure Call: CSJA-2007 20.000€ Period:2008-

Equipment: Cryostate (Leica)
Applicants(s): **Pablo Menendez** for BACM

Infrastructure Call: ISCIII-2007 295.000€ Period:2008-

Equipment: 1.- Cesium Irradiator (Shpefer).
Applicants(s): **Pablo Menendez** for BACM

Infrastructure Call: MINECO-2014 225.000€ Period:2014-

Equipment: 1.- Cesium Irradiator (Shpefer).
Applicants(s): **Pablo Menendez** for IJC

XI.-COLLABORATION AGREEMENTS WITH PHARMA

BCNatal

Amount: 50.000€

Period: 2022

Project: Impact of maternal environment and lifestyle interventions on the susceptibility to fetal (pre)leukemic DNA lesions

PI: **Pablo Menendez**

Onechain Immunotherapeutics SL

Amount: 180.000€.

Period: 2020-2022

Project: Generation of humanized CD22- and CD1a-directed CARs

PI: **Pablo Menendez**

XII.- PUBLICATIONS:

http://scholar.google.com/citations?hl=es&view_op=list_works&gmla=AJsNF6fbIGQv6CBqJHSfqDRqWvnIYhG2tOV64zAkJ47x69XyUoYuo8tbx4AieG0pQrabhG14nNqPJdHg7ZOJl_cc0BfdZ6mNdtzDUpKivHmwBAf3uKk4&user=Aip9aW8AAAAJ&cstart=80&pagesize=20

Nº peer-review international publications: 230

H-Factor: 65 (Google Scholar 01.09.2024)

i10 index: 190 (Google Scholar 01.09.2024)

Accumulated cites: 15.050 (Google Scholar 01.09.2024)

International peer-review publications (published, accepted, in press or submitted):

2024

Nestor Tirado, María J Mansilla, Alba Martínez,.....,Helene Cave, Victor Diaz, Maria L Toribio, Diego Sánchez-Martínez, **Pablo Menéndez***. A dual CCR9- and CD1a-directed CAR-T cell for the treatment of relapsed/refractory T-ALL. In revisión in Blood.

I Zugasti, L Espinosa, V Mulens, M Diaz-Beya, T Velasco, A Urbano, M Juan, J Esteve, **P Menendez***. CAR-T cell therapy for acute myeloid leukemia: current challenges and future directions. **Signal Trans Targeted Ther** 2024; submitted.

Aïda Falgàs, Samanta Zanetti, Rodrigo Lázaro-Gorines, Alberto Orfao, Luis Álvarez-Vallina*,....., Clara Bueno*, **Pablo Menéndez***, A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy 2 in B cell Acute Lymphoblastic Leukemia. In revisión in Blood.

Paolo Petazzi, Julio Castaño, Clara Bueno, Niuska Alvarez, Lesley Forrester, Antonella Fidanza*, Ana Sevilla*, Pablo Menendez*. Generation of an inducible dCas9-SAM human PSC line for endogenous gene activation. In revision in Frontiers Cell Dev Biol.

Mercedes Guerrero-Murillo, Aina Rill-Hinarejos , Juan L. Trincado, Alex Bataller, Valentín Ortiz-Maldonado, Daniel Benitez, Nuria Martinez, Doménica Marchese, Holger Heyn, Manel Juan, Julio Delgado, Álvaro Urbano-Ispizúa, Elisabetta Mereu, Clara Bueno, **Pablo Menendez***. Integrative single-cell multi-omics of CD19-CAR^{pos} and CAR^{neg} T cells suggest drivers of immunotherapy response in B-ALL. In revisión in Cell Rep Med.

Carla Panisello, Rosario Aschero, Alba Martínez, Heleia Roca-Ho, Aïda Falgàs, Azucena González, Julieta Carabelli, Edwards Pradenas, María Lázaro-Díez, Julia G. Prado, Julià Blanco, Jorge Carrillo, Manel Juan, Angel M. Carcaboso, Clara Bueno, **Pablo Menéndez***. NSGS mice humanized with cord

blood mononuclear cells show sustained and functional myeloid-lymphoid representation with limited graft-versus-host-disease. **J ImmunoTher Cancer** 2024; in press

Paolo Pettazi, Telma Ventura, FP Luongo, H McClafferty, A May, HA Taylor, MJ Shipston, N Romanò, LM Forrester*, **Pablo Menendez***, Antonella Fidanza*. A novel human pluripotent stem cell-based gene activation system identifies IGFBP2 as a mediator in the production of hematopoietic progenitors in vitro. **eLIFE** 2024 (in press).

D Sjövall, S Ghos, N Fernandez-Fuentes, T Velasco-Hernandez, A Hogmalm, P Menendez, J Hansson, C Guibentif, P Jaako. Defective ribosome assembly impairs leukemia stem cell function in a murine model of acute myeloid leukemia. **Cell Reports** 2024 (in press).

Srikanth Kodali, Ludovica Proietti,.....**Pablo Menendez**, Jose Luis Sardina, Florian Grebien, Bruno Di Stefano. RNA sequestration in P-bodies sustains myeloid leukemia. **Nat Cell Biol** 2024 (in press).

B Lopez-Millan, A Rubio-Gayarre, M Vinyoles, JL Trincado, J Ramón Tejedor, N Fernandez-Fuentes, JL Sardina, G Valcarcel, F Locatelli, RW Stam, M Bardini, G Cazzaniga, TA Milne, **P Menendez***, Clara Bueno*. NG2 is a target gene of MLL-AF4 that underlies glucocorticoid resistance in infant MLL-rearranged B-ALL by regulating NR3C1 expression through interaction with FLT3. **Blood** 2024 (in press).

Pablo Bousquets-Muñoz, Oscar Molina, Ignacio Varela, Ángel Álvarez-Eguiluz, Javier Fernández-Mateos, Ana Gómez García, Elena Sánchez, Milagros Balbín, Manuel Ramírez-Orellana, Xose Puente*, **Pablo Menéndez***, Talía Velasco*. Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12)(q36;p13) infant AML. **Leukemia** 2024;38(8):1808-1812.

Benítez L, Castro-Barquero S, Crispi F, Youssef L, Crovetto F, Fischer U, Kameri E, Bueno C, Camos M, **Menéndez P**, Heinäniemi M, Borkhardt A, Gratacós E. Maternal lifestyle and prenatal risk factors for childhood leukemia: a review of the existing evidence. **Fetal Diagn Ther.** 2024;51(4):395-410.

S. Mensurado, D. Sanchez-Martínez et al.....**P Menendez***, B Silva-Santos*. CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells. **Blood** 2024;143(15):1488-1495.

T Velasco-Hernandez et al.**P Menendez***. A comprehensive single-cell expression atlas of human AML leukemia-initiating cells unravels the contribution of HIF pathway and its therapeutic potential. **Hemasphere.** 2024;8(2):e45.

L Diaz Alonso, Aida Falgas et al.....**P. Menendez**, C Bueno, L Álvarez-Vallina. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo. **Science Trans Med** 2024; 16(734):eadg7962.

R Safi, **P. Menendez**, Pol. Lipid droplets provide metabolic flexibility for cancer progression. **FEBS Lett** 2024; 598(10):1301-1327.

Oscar Molina, Carmen Ortega-Sabater, Namitha Thampi, Narcís Fernández, Mercedes Guerrero, Alba Martínez-Moreno, Meritxell Vinyoles, Talía Velasco-Hernández, Clara Bueno, Isabel Granada, Carles Giménez, Judit de Boer, Monique den Boer, Gabriel Fernández-Calvo, Mireia Camós, Jose-Luis Fuster, Pablo Velasco, Paola Vallerini, Franco Locatelli, Charles Mullighan, Floris Fojjer, Víctor Pérez-García,

Pablo Menéndez*. Ongoing chromosomal instability across aneuploid subtypes of childhood B-cell ALL associates with disease progression. **EMBO Mol Med** 2024;16(1):64-92.

2023

P.Velasco,....**P.Menendez**,....JL Fuster. The Relapsed Acute Lymphoblastic Leukemia Network (ReALLNet): A multidisciplinary project from the Spanish Society of Pediatric Hematology and Oncology (SEHOP). **Front Pediatrics** 2023;11:1269560.

Yu Wei Zhang, Talia Velasco-Hernandez,, Guy Sauvageau, **Pablo Menendez**, and Nina Cabezas-Wallscheid. GPRC5C Drives Branched-Chain Amino Acid Metabolism in Leukemogenesis. **Blood Adv.** Blood Adv. 2023;7:7525-7538.

Bueno C, Torres-Ruiz R, Molina O, Velasco T, A. Martínez, A Roy, R Marschalek, T Milne, MF Fraga, R Tejedor, **Menendez P***. A human genome editing-based MLL::AF4 B-cell ALL model recapitulates key cellular and molecular leukemogenic features. **Blood** 2023;142:1752-1756.

Talia Velasco-Hernandez and **Pablo Menendez***. Long non-coding RNAs emerge as a novel prognostic indicator in pediatric acute myeloid leukemia. **Transl Pediatr** 2023;12(10):1913-19.

Marin-Bejar O et al**Menendez P**....,Alessandra Giorgetti. Epigenome profiling reveals an aberrant DNA methylation signature in GATA2 deficiency. **Haematologica** 2023;108(9):2551-2557.

Bueno C et al, **P Menendez***. TIM3, a human AML stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell ALL. **Haematologica** 2023. 108(8):2229-2233.

A Lahera, L Vela-Martín, P López-Nieva, RN. Salgado, S Rodríguez-Perales, R Torres-Ruiz,....., **Pablo Menéndez**, J Santos, J Fernández-Piqueras, M Villa-Morales. Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL. **Br J Haematol** 2023; 202(3):693-698.

Mensali N et al.,...., **Menendez P**, Inderberg M, Wälchli S. ALPL-1 is a target for osteosarcoma CAR-based therapy. **Nature Comm** 2023;14(1):3375.

C. Meyer, J. Hofmann, TS. Park.....**P. Menendez**,.....R. Marschalek. The MLL recombinome of acute leukemias in 2023. **Leukemia** 2023;37(5):988-1005.

Tomas-Danza L, et al,...., **P. Menendez**, A. Valencia, BM Javierre. Low input capture Hi-C (liChi-C) identifies promoter-enhancer interactions at high-resolution. **Nature Comm.** 2023;17:14(1)268.

2022

Jiménez-Reinoso A et al,.....**Menendez P***, Vallina L, Sánchez-Martínez D. Efficient treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers. **J ImmunoTher Cancer.** 2022;12(10):e005333.

D Sánchez-Martínez et al.....**P Menendez***. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia. **J ImmunoTher Cancer**. 2022;10(9):e005400.

Petazzi P et al.,...**P. Menendez***, A. Sevilla. N Nogués. ABO gene editing for the conversion of blood type A to universal type O in Rh_{null} donor-derived hiPSCs. **Clin Trans Med**. 2022;12(10):e1063.

Yu Wei Zhang,.....**Pablo Menendez**, Sebastian Walter, Elisa Laurenti, Stefan Günther, Dominic Grün, Nina Cabezas Wallscheid. Hyaluronic Acid–GPRC5C Signalling Promotes Dormancy in Hematopoietic Stem Cells. **Nat Cell Biol**. 2022; 24(7):1038-1048.

M Ramos-Muntada, Juan Luis Trincado et al.... CJ Harrisson, **Pablo Menéndez***, Oscar Molina. Specific chromosomal gains and clonal heterogeneity are risk predictors in childhood high hyperdiploid B-ALL. **Mol Oncol**. 2022, 16(16); 2899-2919.

Clara Bueno, Susana Barrera, JM Ribera, ...,Alvaro Urbano-Ispizúa, Alberto Orfao, Anindita Roy, **Pablo Menéndez***. Pre-leukemic CD34⁺CD19⁻CD22⁺ early B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed immunotherapies. **Blood**. 2022; 140(1):38-44.

Belén Blanco, et al,.....**Pablo Menéndez**, Luis Álvarez-Vallina. Overcoming CAR-mediated CD19 down-modulation and leukemia escape with engineered T lymphocytes secreting anti-CD19 T cell-engaging bispecific antibodies. **Cancer Immunol Res**. 2022;10:498-511.

PA Romecín, M Vinyoles, B López-Millán, R Diaz de la Guardia, S Querol, C Bueno R Benitez, E Gonzalez-Rey, M Delgado, Pablo Menéndez. Development of an inducible caspase-9 safety switch for mesenchymal stem cell-based therapies. **Stem Cells Transl Med**. 2022;11:88-96.

Oscar Molina, Alex Bataller, Namitha Thampi, Jordi Ribera, Isabel Granada, Pablo Velasco, José Luis Fuster and **Pablo Menéndez***. Near-haploidy and low-hypodiploidy in B-cell acute lymphoblastic leukemia: when less is too much. **Cancers** 2022;14:32-54.

Belen Lopez-Millan, Paula Costales, Francisco Gutiérrez-Agüera, Rafael Díaz de la Guardia, Heleia Roca-Ho, Paola Romecín, Meritxell Vinyoles, Manuel Ramírez-Orellana, Eduardo Anguita, Irmela Jeremias, Juan Carlos Rodríguez-Manzanaque, Clara Bueno, Francisco Morís, **Pablo Menendez***. The multi-kinase inhibitor EC-70124 is a promising candidate for the treatment of FLT3-ITD-positive acute myeloid leukemia. **Cancers** 2022;21:14(6):1593.

Miguel A Galindo-Campos, Nura Lutfi, **Pablo Menéndez**, Julian Sale, José Yélamos. Differential functional roles for PARP-1 and PARP-2 in c-Myc-driven B cell lymphoma in mice. **Blood** 2022;139:228-239.

V Rodríguez-Cortez, O Molina et al..... A Bigas, A Terron, C Bueno, **Pablo Menéndez***. The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells. **Haematologica**. 2022; 107(2):544-549.

SR Zanetti, T Velasco-Hernandez, F Gutierrez, PA Romecín, H Roca-Ho, D Sánchez-Martínez, ML Baroni, P Petazzi, R Torres, JL Fuster, P Ballerini, M Juan, I Jeremias, C Bueno, **P Menéndez***. A novel and efficient tandem CD19- and CD22-directed CAR for B-cell ALL. **Mol Therapy** 2022; 30(2):550-563.

2021

A Bataller, F Guijarro, O Molina, P Chevallier, M Zaliova, J Zuna, L Magnano, N Grardel, P Cornillet-Lefebvre, JF Fu, L Yung-Shih, T Boneva, E Nacheva, S Beà, M López-Guerra, C Bueno, **P Menéndez**, J Esteve, P Larghero, C Meyer, R Marschalek. *KTM2A-CBL* rearrangements in acute leukemias: clinical characteristics and genomic breakpoints. **Blood Adv** 2021; 5(24): 5617-5620.

T Jaffredo et al.....Pablo **Menendez**,.....JJ Schuringa. The EHA Research Roadmap: Normal Hematopoiesis. **Hemasphere** 2021;5:12e669.

M Ribeiro, D Reyes-Garau, M Vinyoles, et al...M Esteller, F Bosch, **P Menéndez**, E Normant, G Roue. Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling in B-cell non-Hodgkin lymphoma. **Clin Cancer Res.** 2021,27(23):6591-6601.

R Díaz de la Guardia, B Lopez-Millan, T Velasco-Hernandez, F Gutiérrez-Agüera, H Roca-Ho, O Molina, C Nombela, A Bataller, JL Fuster, E Anguita, S Vives, J Nomdedeu, M Gómez-Casares, M Ramírez-Orellana, H Lapillonne, C Bueno, **P Menéndez***. Characterization of the engraftment of risk-stratified AML patients in NSGS mice. **Blood Adv** 2021; 5(23):4842-4854

A Manzano-Muñoz, C Alcon, **P Menéndez**, M Ramírez, F Seyfried, D Klaus-Michael, LH Meyer, J Samitier, J Montero. MCL-1 inhibition overcomes anti-apoptotic adaptation to targeted therapies in B-cell acute lymphoblastic leukemia. **Front Cell Dev Biol** 2021;21:9:636704.

J García-Castillo, F Alcaraz-Pérez, E Martínez-Balsalobre, D García-Moreno, M Bernabé-García, MP Rossmann, AB Pérez-Oliva, V Rodríguez, C Bueno, I Adatto, S Agarwal, **P Menéndez**, LI Zon, V Mulero, ML Cayuela. Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. **Proc Natl Acad Sci USA.** 2021;118 (32) e2015528118.

JR Tejedor, C Bueno, et al..... I Varela, MF Fraga, AF Fernández, **P Menéndez***. Integrative methylome-transcriptome analysis unravels cancer-cell vulnerabilities in infant MLL-rearranged B-cell acute lymphoblastic leukemia. **J Clin Invest.** 2021.131:e138833.

F Gutiérrez-Aguera, V. Rodriguez-Cortez, P. Petazzi, C. Bueno, **P. Menendez***. A benchmarking comparison of two well-established protocols for hematopoietic differentiation from hPSCs. **Front Cell Dev Biol** 2021;9:636704.

O de Barrios, A Galaras, JL. Trincado, A Azagra, O Collazo, A Meler, A Agraz-Doblas, C Bueno, I Varela, P de Lorenzo, MG Valsecchi, P Hatzis, **P Menéndez**, M Parra. HDAC7 is a major contributor in the pathogenesis of t(4;11)/MLL-AF4+ infant B-cell Acute Lymphoblastic. **Leukemia.** 2021;35:2086-2091.

D Sanchez-Martínez, F Gutiérrez-Agüera, P Romecin, N Tirado, M Vinyoles, M Palomo, SR Zanetti, M Juan, I Jeremias, **P. Menendez***. Enforced sialyl-Lewis-X display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and BM homing. **Clin Transl Medicine** 2021;11:e280.

O. Molina, MA Abad, F Sole, **P. Menendez***. Aneuploidy in B-cell acute lymphoblastic leukemia. **Trends in Cancer** 2021;7(1):37-47.

L Godfrey, NT Crump, S O'Byrne, O. Heidenreich, P Vyas, **P. Menendez**, S Inglott, P Ancliff, H Geng, I Roberts, A. Roy, TA. Milne. H3K79me2/3 controls enhancer promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. **Leukemia**, 2021;35:90-106.

2020

P Petazzi, **P Menéndez**, A Sevilla. CRISPR/Cas9-mediated gene knock-out and knock-in human iPSCs. **Methods Mol Biol** 2020;136:1845-47.

M Martinez-Lage, R Torres-Ruiz, P Puig P Moreno-Gaona M Martin, F Moya, O Quintana-Bustamante, S Garcia-Silva, Angel Carcaboso, P Petazzi, C Bueno, J Mora, H Peinado, JC Segovia, **Pablo Menéndez**, S Rodríguez-Perales. In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. **Nature Communications**. 2020;11:5060.

P. Petazzi, **P. Menendez***. A NEWral approach for HSCs production in vitro? **BLOOD** 2020;136: 1845-47.

SR Zanetti, PA Romecín, M Vinyoles, M Juan, JL Fuster, M Camós, S Querol, M Delgado, **P Menéndez***. Bone marrow MSC from B-ALL patients highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity. **J ImmunoTherapy Cancer** 2020;8(2):e001419.

T Velasco-Hernandez, S. R Zanetti, H Roca-Ho, F. Gutiérrez-Agüera, P. Petazzi, D. Sanchez-Martínez, O. Molina, ML. Baroni, JL, Fuster, P. Ballerini, C. Bueno, P. Engel. **P. Menendez***. Efficient elimination of primary B-ALL cells *in vitro* and *in vivo* by a novel 4-1BB-based CAR targeting a membrane distal CD22 epitope. **J ImmunoTherapy Cancer** 2020.8(2);e000896.

C. Bueno, P Ballerini, I. Varela, **P.Menendez***, R. Bashford-Rogers*. Shared D-J rearrangements reveal cell of origin of *TCF3-ZNF384* and *PTPN11* mutations in monozygotic twins with concordant BCP-ALL. **Blood**. 2020;136:1108-1111.

M Baroni, D Sanchez-Martínez, F Gutierrez, M Castella, SR Zanetti, T Velasco-Hernández, R de la Guardia, J Castaño, E Anguita, S Vives, JF Nomdedeu, H Lapillonne, AE Bras, VHJ van Velden, J Junca, I. Jeremias, A López, M Sorigue, C Bueno, **P Menéndez***. 4-1BB- and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis *in vivo*. **J ImmunoTherapy Cancer** 2020;8(1):e000845.

O Molina, C Bueno, I Granada, H Roca-Ho, F Gutierrez-Agüera, S Tirados, D Pal, P Ballerini, M den Boer, I Plensa, S Rodríguez-Perales, MJ Calasanz, M Ramírez-Orellana, R Rodríguez, M Camós, M Calvo, **P Menendez**. Impaired Condensin Complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL. **Blood** 2020;136:313-327.

I. Mirones et al.,...,**P. Menendez** & A Pérez-Martínez. Immunotherapy with CAR-T cells in pediatric hematology-oncology. **Ann Pediatr** 2020;S1695-4033(20)30016-3.

P Petazzi, R Torres, A Fianza, H Roca-Ho, F Gutierrez-Agüera, R Díaz de la Guardia, B López-Millán, A Bigas, L Forrester, C Bueno, **P Menéndez***. Comparison of dead Cas9 activators in human pluripotent and mesenchymal stem cells. **Molecular Therapy Nucleid Acids** 2020;20:196-204.

L Beneforti, E Dander, S Bresolin, C Bueno, A Ford, B Gentner, G te Kronnie, P Vergani, **P Menéndez**, A Biondi, G D'Amico, C Palmi, G Cazzaniga. Inflamed bone marrow mesenchymal stromal cells provide advantage to ETV6-RUNX1-positive pre-leukemic cells. **Br J Haematol** 2020;190:262-273

R Diaz de la Guardia, L Gonzalez-Slva, B Lopez-Millán, J Rodríguez-Sevilla, M L Baroni, C Bueno, E Anguita, S Vives, L Palomo, H Lapillonne, I Varela, **P Menendez***. Bone marrow clonogenic myeloid progenitors from *NPM1*-mutated AML patients do not harbor the *NPM1* mutation: implication for the cell-of-origin of *NPM1*+ AML. **Genes** 2020;11:73-77.

A Vidal, A Matas, V Rodriguez, C Rossi, **P Menendez**, G Roué, A López-Guillermo, E Giné, E Campo, D Colomer, A. Wiestner, C Bezombes, C Chiu, P Doshi, P Pérez-Galán. Daratumumab displays anti-tumor activity in *in vitro* and *in vivo* models of B cell non-Hodgkin lymphoma and improves response to standard chemo-immunotherapy regimens. **Haematologica** 2020.105;4:2032-2041.

2019

S O'Byrne, N Elliott, G Buck, S Rice, D Knapp,....., **P Menendez**, TA Milne, I Roberts, A Roy. Reordering B-lymphopoiesis in the human fetus identifies ontogeny-related developmental programmes in common with infant leukaemia. **Blood** 2019;134:109-1071.

C Bueno, JR Tejedor, R Bashford-Rogers, L González-Silva, R Valdés-Mas, A Agraz-Doblás, R Díaz de la Guardia, C Bilhou-Nabera, N Abermil, H Guermouche, E Gouache, G Leverger, MF Fraga, AF Fernández, P Ballerini, I Varela, P Menendez. Natural history and cell-of-origin of *TCF3-ZNF384* & *PTPN11* mutations in twins with concordant B-ALL. **Blood** 2019;134:900-905.

J Castaño, S Aranda, C Bueno, FJ Calero-Nieto, E Mejia-Ramirez, E Blanco, X Wang, C Prieto, L Zabaleta, M Rovira, B Göttgens, L Di Croce, **P Menendez**, Angel Raya, A Giorgetti. GATA2 promotes hematopoietic development and represses cardiac differentiation of human mesoderm. **Stem Cell Rep** 2019;13;1-15.

D Sánchez-Martínez, ML Baroni, F Gutierrez-Agüera, H Roca-Ho, O Blanch-Lombarte, T Velasco, C Bueno, JL Fuster, J Garcia-Prado, J Cools, M Camos, F Pflumio, ML Toribio, **P Menéndez**. Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia. **Blood** 2019;133:2291-2304.

R. Urdinguio, V. López, G. Bayón,..... **P. Menéndez**,....., R. Deutzmann, AF. Fernandez, M. F. Fraga. Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment. **Nucleid Acid Res** 2019;72:5016-5037.

C. Bueno, T. Velasco, F Gutierrez, S. Zanetti, D. Sánchez, M. Baroni, O. Molina, A. Closa, A. Agraz, E. Eyra, I. Varela, P. **Menendez***. CD133-directed CAR T cells for MLL leukemia: on target off-tumor myeloablative toxicity. **Leukemia** 2019; 33:2120-2125.

A. Agraz-Doblas, C.Bueno, R.Bashford-Rogers, A. Roy, P.Schneider, P. Ballerini, G. Cazzaniga, M.Bardini, I.Robers, R. Pieters, I. Varela, RW.Stam, **P.Menendez***. Unravelling the cellular origin and

clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. **Haematologica** 2019;104:1176-1188.

C Bueno, F Calero-Nieto, X Wang, R Valdés-Mas, H Roca-Ho, F Gutiérrez-Agüero, V Ayllon, PJ Real, D Arambilet, L Espinosa, A Bigas, B Gottgens, R Marschalek, **P Menendez***. Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between *AF4-MLL* and *MLL-AF4* fusions. **Haematologica** 2019;104:1189-1201.

Lopez-Millán, H. Roca-Ho, R. Diaz Guardia, D. Sánchez-Martínez, F. Gutiérrez-Agüera, JL. Fuster, P. Ballerini, C. Nombela-Arrieta, C. Bueno, **P. Menendez***. NG2 antigen is a therapeutic target for MLL-rearranged B-cell ALL. **Leukemia** 2019; 33:1557-1569.

R. Diaz de la Guardia, B Lopez-Millan, H Roca-Ho, C Bueno, F Gutiérrez-Agüera, JL Fuster, E Anguita, S Vives, J Nomdedeu, R Sackstein, J Lavoie, E González-Rey, M Delgado, M Rosu-Myles, **P Menendez***. BM-MSCs from risk-stratified AML patients are anti-inflammatory in *in vivo* preclinical models of hematopoietic reconstitution and severe colitis. **Haematologica** 2019;104:e54-e58.

C. Recasens-Zorzo,....., **P. Menéndez**, A. López-Guillermo, JI. Borrell, L. Colomo, P. Pérez-Galán, G Roué. Pharmacological modulation of CXCR4 potentiates the activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma. **Haematologica** 2019;104:778-788.

2018

M. Martinez-Lage, P. Puig-Serra, **P. Menendez**, R. Torres-Ruiz, S. Rodriguez-Perales. CRISPR/Cas9 For Cancer Therapy: Hopes and Challenges. **Biomedicines** 2018: 6.E105.

E. Garcia-Alegría,**P. Menendez**, G Lacaud, V. Kouskoff. CD31 expression marks multilineage potential and definitive hematopoiesis during in vitro human hematopoietic differentiation. **Stem Cell Reports**. 2018;11:1061-1107.

M Castella, A Boronat, R Martín-Ibáñez, V Rodríguez, M Caballero, B Marzal, J Castaño, C Bueno, Olga Balagué, C Serra, P Engel, R Vilella, D Benitez, J Tabera, JM Canals, M Lozano, A Vilarrodona, E Trias, E Campo, **P Menéndez**, A Urbano, J Yagüe, P Pérez-Galán, S Rives, J Delgado, M Juan. Development of a novel anti-CD19 chimeric antigen receptor for a Spanish approved clinical trial: a paradigm for an affordable CAR T cell production at academic institutions. **Mol Ther Methods Clin Dev** 2018;12:134-144.

AF. Fernandez, GF. Bayón,**P. Menendez**,....., F. Bonilla, and MF. Fraga. DNA hydroxymethylation at H3K4me2-rich regions predicts non-canonical aberrant DNA hypermethylation in glioma. **Hum Mol Genetics** 2018;27:3046-3059.

K Otterbasch, A Sanjuan-Pla, R Torres-Ruiz, C Bueno, T Velasco, **P Menendez***. Revisiting current and “never-ending” mouse models for *MLL* acute leukemia. **HemaSphere** 2018;2:1-6.

B. Lopez-Millan, R. Diaz, H.Roca, et al.....**P. Menendez***. IMiDs mobilize Acute Myeloid Leukemia blasts to peripheral blood through downregulation of CXCR4 but do not potentiate AraC/Idarubicin activity in preclinical models of 5q- AML. **Oncoimmunology** 2018;7(9): e1477460.

J Tejedor, C Bueno, I Cobo, G Bayón, C Prieto, C Mangas, P Santamarina, R Urdinguio, **P Menendez**, MF Fraga, & AF Fernández. Epigenome-wide analysis reveals specific DNA hypermethylation of T cells during human hematopoietic differentiation. **Epigenomics** 2018;2:903-23.

M. García-Peydro, P Fuentes, M Mosquera, M García-León, P. García de Miguel, K. Weijer, H Spits, C Cuesta-Mateos, **P. Menendez**, D Scadden, C Muñoz-Calleja, F Sanchez-Madrid, ML Toribio. A novo in vivo model of human T-ALL generation identifies CD44 as a Notch1 target required for leukemia-initiating cell activity. **J Clin Invest** 2018;128: 2802-18.

C Prieto, R W Stam, FJ Rodríguez-Baena, D Romero-Moya, A Sanjuan-Pla, V Ayllón, M Ramírez, M Bardini, P De Lorenzo, M Stanulla, M Iglesias, P Ballerini, ÁM Carcaboso¹¹, JMora, F Locatelli, A Bertaina, JC Rodríguez, C Bueno, **P Menéndez***. Neural Glial Antigen 2 is involved in Leukemia Invasiveness and Central Nervous System Infiltration in MLL-rearranged Infant B-ALL. **Leukemia** 2018;32:633-644.

Diaz de la Guardia R, Correa JG, Lopez-Millan MB, Bueno C, Juan M, Cervantes F, **Menendez P***. Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. **Br J Haematol** 2018; 181:133-137.

C. Meyer, J. Hofmann, TS. Park.....**P. Menendez**,.....R. Marschalek.. The MLL recombinome of acute leukemias in 2017. **Leukemia** 2018;32:273-284.

2017

S Body, A Esteve, H Miloudi, C Recasens, **P. Menendez**, P Perez, F Jardin, G Roue, B Sola. Cytoplasmic Cyclin D1 controls migration and invasion of mantle lymphoma cells. **Sci Reports** 2017; 7:13946.

M. Martin-Lopez, L. Maeso-Alonso, S. Fuertes-Alvarez, D. Balboa-Alonso, I. Diez-Prieto, T Otonkoski, P. **Menendez**, M. Marqués, C. Marín. p73 is required for appropriate BMP-induced Mesenchymal to Epithelial Transition during somatic cell reprogramming. **Cell Death Dis** 2017;8:e3034.

Sierra M, Rubio L, Bayón G, Cobo I, **Menendez P**, Morales P, Mangas C, Urdinguio R, Marcos R, Torrecillas R, Fernández AF, Fraga MF. X-chromosome DNA hypomethylation in human lung epithelia cells exposed to multi-wall carbon nanotubes. **Nanotoxicology** 2017;11:857-870.

J Domingo-Reinés, A. López-Ornelas, R. Montes, T. Romero, JL. Rodríguez-Lamas, F. González-Pozas, V. Ayllón, **P. Menendez**, I. Velasco, V. Ramos-Mejía. Hoxa9 and EGFP reporter expression in hES cells as useful tools for studying human development. **Stem Cell Res** 2017;25:286-290.

I. Varela, **P. Menendez**, A. Sanjuan-Pla. Intratumor heterogeneity and clonal evolution in blood malignances and solid tumors. **Oncotarget** 2017;8:66742-46.

O. Navarro, V Ayllón, V Ramos-Mejia, R. Montes, C Bueno, E. Ng, M. Lamolda, X.Guerrero, L. Lopez-Onieva, T. Romero, D. Romero, E. Stanley, A. Elefanty, PJ Real, **P. Menendez***. RUNX1c regulates hematopoietic specification from human ESCs through activation of pro-inflammatory signaling. **Stem Cells** 2017;35:2253-2266.

R.Torres-Ruiz, S. Rodriguez-Perales, C. Bueno, **P. Menendez**. Modelling MLL-rearranged Leukemia initiation in CD34+ cells: A “CRISPR” solution. **Haematologica** 2017;102:1467-1468.

C. Bueno, **P. Menendez**. Human acute leukemia iPSCs: a unique model for investigating disease development and pathogenesis. **Stem Cell Investig** 2017;4:55-59.

A Gentilella FD Morón-Duran, P Fuentes, G Zweig-Rocha, F Riaño-Canalias, J Pelletier, M Ruiz, G Turón, J Castaño, A Tauler, C Bueno, **P Menéndez**, SC Kozma and G Thomas. Autogenous control of 5'TOP mRNA stability by 40S ribosomes. **Mol Cell**;2017;67:55-70.

C Prieto, R. Marchalek, A. Ruhn, A. Bursen, C Bueno & **P. Menendez**. The AF4-MLL fusion transiently augments multilineage hematopoietic engraftment but is not sufficient to initiate leukemia in cord blood CD34+ cells. **Oncotarget** 2017;8:81936-81941.

O. Pelkonen, A. Terron, A. Hernandez, **P. Menendez**, S. Hougaard, on behalf of the EFSA WG EPI. Chemical exposures and infant leukaemia: development of an adverse outcome pathway (AOP) for etiology and risk assessment research. **Arch Toxicology** 2017;91:2763-80.

D. Romero-Moya, C Santos-Ocaña, J Castaño, G Garrabou, JA Rodríguez-Gómez, V Ruiz-Bonilla, E Perdiguero, C Bueno, C Moren-Nuñez, P González-Rodríguez, A Giorgetti, C Prieto, Á Muñoz-López, I Velasco, J López-Barneo, F Cardellach, R Artuch, P Muñoz-Cánoves, P Navas, **Pablo Menéndez***. Genetic rescue of mitochondrial and skeletal muscle impairment in an iPSC model of coenzyme Q₁₀ deficiency. **STEM CELLS**. 2017;35:1687-1703.

R. Torres-Ruiz, M. Martinez-Lage, MC. Martin, A. Garcia, C. Bueno, J. Castaño, JC. Ramirez, **P Menendez**, J.C. Cigudosa and S. Rodriguez-Perales. Efficient generation of t(1;22) EWSR1-FLI1+ in human stem cells using CRISPR-Cas9. **Stem Cell Rep** 2017;8:1408-20.

J. Castaño, C Bueno, S Jiménez-Delgado, H. Roca-Ho, M. Fraga, A. Fernández, R Torres-Ruiz, S. Rodriguez-Perales, **P. Menendez**. Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the “safe harbor” AAVS1 locus. **Stem Cell Res** 2017;21:127-40.

EFSA Panel on Plant Protection Products and their residues (PPR), Ockleford C, Adriaanse P, Berny P, Brock T, Duquesne S, Grilli S, Hernandez-Jerez AF, Bennekou SH, Klein M, Kuhl T, Laskowski R, Machera K, Pelkonen O, Pieper S, Smith R, Stemmer M, Sundh I, Teodorovic I, Tiktak A, Topping CJ, Wolterink G, Angeli K, Fritsche E, Hernandez-Jerez AF, Leist M, Mantovani A, **Menendez P**, Pelkonen O, Price A, Viviani B, Chiusolo A, Ruffo F, Terron A, Bennekou SH. **EFSA Journal**. 2017;15:e04691.

R Díaz de la Guardia, B Lopez-Millán, C Bueno, J Castaño, M Gómez-Casares, S Vives, L Palomo, M Juan, L Blanco, J Nomdedeu, JL Fuster, M Rosu-Myles, J Lavoie, E Anguita, **P Menéndez***. Functional, genetic and immunological characterization of bone marrow-derived mesenchymal stromal cells from Acute Myeloid Leukemia patients. **Stem Cell Rep** 2017;8:1573-86.

A. Macia, T. Widmann, M. Benkaddour-Boumzaouad, M. Muñoz-Lopez, S. Amador-Cubero, L. Sanchez, V. Ayllon, **P. Menendez**, J. Garcia-Castro, AR. Muotri, P. Ng, JL. Goodier, JL. Garcia-Perez. Engineered LINE-1 retrotransposition in human neurons. **Genome Res** 2017;27: 335-348.

B. Lopez-Millán, R. Diaz de la Guardia, H. Roca-Ho, C M García-Herrero, JR Lavoie, M Rosu-Myles, M Delgado, G Criado & **P Menendez***. Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. **Exp Mol Med** 2017; 49:e290.

A. Giorgetti, J Castaño, R Diaz-de la guardia, C Bueno, M Delgado, L Espinosa, **P Menendez***. Pro-inflammatory signaling is dispensable for hematopoietic emergence of human pluripotent stem cells. **Exp Hematol.** 2017;45:85-93.

A Matas, A Vidal, V Rodriguez, N Villamor, J Delgado, E Gine, H Roca, **P Menéndez**, E Campo, AL Guillermo, D Colomer, G Roué, A Wiestner, P Parren, P Doshi, J Lammerts, P Pérez-Galán. The human CD38 MoAb daratumumab shows anti-tumor activity and hampers leukemia microenvironment interactions in chronic lymphocytic leukemia. **Clin Cancer Res**; 2017;23:1493-1505.

2016

D. Romero-Moya, J Castaño, C. Santos-Ocaña, P. Navas, **P Menendez***. Generation, genome edition and characterization of iPSC lines from a patient with coenzyme Q₁₀ deficiency harboring a heterozygous mutation in *COQ4* gene. **Stem Cell Res** 2016; 30122-26.

A. Muñoz-Lopez, D. Romero, C. Prieto, V. Ramos-Mejía, A. Agraz-Doblas, I. Varela, M. Buschbeck, A. Palau, X. Carvajal-Vergara, A. Giorgetti, A. Ford, M. Lako, I. Granada, S. Rodríguez-Perales, R Stam, M. Fraga, M. Nakanishi, G. Cazzaniga, M. Bardini, I. Cobo, G Bayon, A. Fernandez, C. Bueno, **P. Menendez***. Differentiation refractoriness of MLL-rearranged human B-cell acute leukemias to reprogramming into pluripotency. **Stem Cell Rep** 2016;7:602-18.

J. Castaño, A Herrero, A Bursen, R Marschalek, N Gutiérrez, **P Menendez***. Expression of MLLAF4 and AF4MLL does not impact the efficiency of DNA damage repair. **Oncotarget** 2016; 7:30440-30452.

AF Hernandez, **P. Menendez***. Linking pesticide exposure to pediatric leukemia: potential underlying mechanisms. **Int J Mol Sci** 2016; 17:461-478.

E Gonzalo-Gil, MJ Pérez-Lorenzo, M Galindo, R Díaz de la Guardia, B López-Millán, C Bueno, P Menéndez, JL Pablos, G Criado. Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase. **Arthritis Research & Therapy** 2016; 18: 77-85.

A. Engert,....., **P Menendez**,....., Zieger B. The European Hematology Association Roadmap for European Hematology Research. A Consensus Document. **Haematologica** 2016; 101:115-208.

C Prieto, R Stam, A Agraz-Doblas, P Ballerini, M Camos, R Marschalek, A Bursen, I Varela, C Bueno, **P Menendez**. Activated *KRAS* cooperates with MLL-AF4 to promote extramedullary engraftment and migration of cord blood CD34⁺ HSPCs but is not sufficient to initiate leukemia. **CANCER RES** 2016; 76: 2478-89.

A Muñoz-López, Eddy van Roon, R Stam, D Romero-Moya, B López-Millan, D Colomer, M Nakanishi, C Bueno & **P Menendez**. Cellular ontogeny and hierarchy influence the reprogramming efficiency of human B-cells to induced pluripotent stem cells. **STEM CELLS** 2016;34:581-587.

C Bueno, E.H.J van Roon A. Muñoz-López, A Sanjuan-Pla, M Juan, A. Navarro, R. Stam, **P. Menendez***. Immunophenotypic analysis and quantification of B-1 and B2 B-cells during human fetal hematopoietic development. **LEUKEMIA** 2016; 30:674-682.

A. Sanjuan-Pla, D Romero-Moya, C Prieto, C Bueno, A Bigas, **P. Menendez***. Intra-bone marrow transplantation confers superior multilineage engraftment of murine AGM cells than intravenous transplantation. **Stem Cells Dev** 2016;25:259-265.

C Bueno, JL Sardina, B. di Stefano, D Romero-Moya, MC Chillón, A Balanzategui, A. Muñoz-López, J Castaño, A Herreros, MF Fraga, A Fernández, D Campos, I Granada, O Quintana-Bustamante, JC Segovia, K Nishimura, M Ohtaka, T Graf, M Nakanishi & **P Menendez**. Reprogramming human B-cells into induced pluripotent stem cells and its enhancement by C/EBPa. **LEUKEMIA** 2016;30:674-682.

2015

A. Sanjuan-Pla, C. Bueno, C. Prieto, P. Acha, R.W. Stam, R. Marschalek, **P. Menendez***. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. **BLOOD** 2015; 126:2676-85.

C. Soria-Valles, FG. Osorio, A. Gutiérrez-Fernández, A. de Los Angeles, C. Bueno, **P. Menéndez**, GQ. Daley, JMP. Freije & C. López-Otín. NF-κB activation impairs somatic cell reprogramming in ageing. **NATURE CELL BIOL** 2015;17:1004-1013.

V. Ayllon, C. Bueno, V. Ramos, P. Real, T. Romero, O. Navarro, MJ, García-León, ML. Toribio, A. Bigas. **P. Menendez***. The Notch ligand DLL4 marks human hematoendothelial progenitors and regulates their hematopoietic vs endothelium fate. **LEUKEMIA** 2015; 29: 1741-1753.

MJ. Pino-Barrio, E. García-García, **P. Menéndez**, A Martínez-Serrano. V-Myc immortalization of human neural stem cells induces self-renewal without activating a complete reprogrammed-like status. **PLoS ONE** 2015; 10: e0118499.

A. Alfranca, L. Martínez-Cruzado, Juan Tornín, Ander Abarrategi, Teresa Amaral, Enrique de Alava, **Pablo Menéndez**, Javier García-Castro, René Rodríguez. Bone microenvironment signals in osteosarcoma development. **CELL MOL LIFE SCI**. 2015; 72: 3097-3113.

S. Qi, Z. Fang, D. Wang, **P. Menendez**, K. Yao, J. Ji. Induced Pluripotency by Defined Factors: Prey of Oxidative Stress. **STEM CELLS** 2015; 33:1371-1376.

M. Toscano, O. Navarro-Montero, V. Ayllon, V. Ramos-Mejia, C. Bueno, T. Romero, M. Cobo, F. Martin, **P. Menendez***, P. Real*. SCL/TAL1-mediated transcriptional network enhances megakaryocytic differentiation of human embryonic stem cells. **MOL THER** 2015; 23:158-170.

B. Martín-Antonio, A. Najjar, S. Robinson, C. Chew, S. Li, E. Yvon, M. Thomas, I. McNiece, R. Orlowski, C. Munoz-Pinedo, C. Bueno, **P. Menendez**, C. Fernández de Larrea, A Urbano-Ispizua, E. Shpall, N.

Shah. Transmissible Cytotoxicity Of Multiple Myeloma Cells By Cord Blood-Derived NK Cells Is Mediated By Vesicle Trafficking. **CELL DEATH DIFF** 2015; 22:96-107.

A. Fernández, G. Bayón, RG. Urdinguio, EG. Toraño, M. García, A. Carella, S. Petrus-Reurer, C. Ferrero, P. Martínez-Cambor, J. García-Castro, J. Delgado, J. Riancho, C. Bueno, **P. Menéndez**, A. Mentink, K. Mareschi, F. Claire, C. Fagnani, E. Medda, V. Toccaceli, S. Brescianini, S. Moran, M. Esteller, A. Stolzing, J. de Boer, L. Nisticò, MA. Stazi, MF. Fraga. H3K4me1 marks DNA regions hypomethylated during aging in stem and differentiated cells. **Genome Res** 2015; 25:27-40.

2014

J. Guiu, DJ. Bergen, K. Islam, V. Ayllón, L. Norton, C. Ruiz-Herguido, N. López-Bigas, **P. Menéndez**, L. Espinosa, A. Bigas. Identification of CDCA7 as a novel Notch transcriptional target involved in Hematopoietic Stem Cells emergence. **J Exp Med** 2014;211: 2411-2423.

A. Freije, L. Ceballos, M. Cagigas, R. Molinuevo, P. Alonso, R. Rodriguez, **P. Menendez**, E. de Diego, A. Gandarillas. Inactivation of p53 forces expel of human epidermal cells via replication stress, mitotic slippage and squamous differentiation. **Cell Rep** 2014; 9:1349-1360.

J. Castaño*, **P. Menendez***, C. Bruzos, A. Sousa, M. Straccia, L. Zabaleta, N. Vazquez, A. Zubiarrain, J. Maria Canals, L. Ugedo, X. Carvajal-Vergara, M. Torrecilla, R. Sanchez-Pernaute, A. Giorgetti. Rapid and efficient neural conversion of human hematopoietic cells by SOX2 and c-MYC Sendai vectors. **Stem Cell Rep** 2014;3: 1118-1131. * co-first author.

V. Ramos-Mejía, O. Navarro-Montero, V. Ayllón, C. Bueno, T. Romero, P.J. Real, **P. Menendez***. HOXA9 promotes hematopoietic commitment of human embryonic stem cells. **Blood** 2014; 124:3065-3075.

R. Rodríguez, M. Rosu-Myles, M. Araúzo, E. González-Rey, M. Delgado, **P. Menendez***. Human bone marrow stromal cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation. **Stem Cells Reports** 2014;3:606-619.

I. Velasco, P. Salazar, D. Romero-Moya, V. Ramos-Mejia, A. Giorgetti, **P. Menendez***. Generation of neurons from healthy individuals and neurological patients through induced pluripotency and direct conversion. **Stem Cells** 2014;32:2811-2817.

C. Bueno, M. Roldán, E. Anguita, D. Romero-Moya, M. Rosu-Myles, C Cañizo, R. García, M. Gómez-Casares, JL. Fuster, M. Jurado, M Delgado, **P. Menendez***. Bone marrow mesenchymal stem cells from patients with aplastic anemia preserve functional and immune properties and do not contribute to the pathogenesis of the disease. **Haematologica** 2014;99:1168-1175.

RM. Rodriguez, B. Suarez-Alvarez, R. Salvanés, C. Huidobro, EG. Toraño, JL. Garcia-Perez, C. Lopez-Larrea, AF. Fernandez, **P. Menendez** and MF. Fraga. Role of BRD4 in hematopoietic differentiation of embryonic stem cells. **Epigenetics** 2014;9:566-578.

R. Rubio, A. Abarrategi, J. García-Castro, C. Suárez, J. Tornín, L. Santos, I. Colmenero, **P. Menendez***, R Rodríguez. Bone microenvironment signals are essential for osteosarcoma development from p53- and Rb-deficient mesenchymal stem cells. **Stem Cells** 2014;32:1136-1148.

M. Pérez-Mato, P. Ramos-Cabrero, T. Sobrino, M. Blanco, A. Ruban, D. Mirelman, **P. Menendez**, J. Castillo, F. Campos. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. **Cell Death & Dis** 2014;5:992-1001.

R. Montes, A. Bursen, R. Marschalek, C. Prella, C. Chillón, D. Romero-Moyá, C. Prieto, O. Navarro-Montero, C. Bueno, **P. Menendez***. Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. **Leukemia** 2014;28:666-674.

2013

R. Rodriguez, J. Tornín, C. Suárez, R. Rubio, M. Rosu-Myles, A. Williams, C, JM. Funes, C. Boshoff, **P. Menendez***. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stromal/stem cells drives mixoid liposarcoma formation. **STEM CELLS** 2013;31:2061-2072.

P.J. Real, O. Navarro-Montero, V. Ayllón, V. Ramos-Mejía, C. Bueno, **P. Menendez***. The role of RUNX1 isoforms in hematopoietic commitment from human pluripotent stem cells. **BLOOD** 2013 121:5250-5252.

C. Meyer, J. Hofmann, TS. Park.....**P. Menendez**,R. Marschalek. (MLL RECOMBINOME CONSORTIUM). The MLL recombinome of acute leukemias in 2013. **LEUKEMIA** 2013; 27: 2165-2176.

Bueno C, Ayllón V, Montes R, Romero-Moya D, Navarro-Montero O, Ramos-Mejía V, Real PJ, Araúzo-Bravo M, **Menendez P***. FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of hESCs. **BLOOD** 2013;121:3867-3878.

D. Romero-Moya, C. Bueno, R. Montes, O. Navarro-Montero, F.J. Iborra, M. Martín, **P. Menéndez***. Cord blood CD34+ hematopoietic cells with low levels of mitochondrial mass are enriched in hematopoietic repopulating stem cell function. **Haematologica** 2013; 98:1022-9

M. Rosu-Myles, J. McCulley, J. Fair, J. Mehic, **P. Menendez**, R. Rodríguez, C. Westwood. "The globo-series glycosphingolipid SSEA-4 is a marker of clonal multipotent stromal cells in vitro and in vivo". **Stem Cells Dev** 2013; 22: 1387-1397.

R. Rubio, I. Gutierrez-Aranda, A. Saez, A. Labarga, **P. Menendez***, **R. Rodríguez***. The differentiation stage of p53 and Rb-deficient Mesenchymal Stem Cells imposes the phenotype of in vivo sarcoma development. **Oncogene** 2013; 32:4970-4980.

2012

O. Navarro-Montero, D. Romero-Moya, R. Montes, V. Ramos-Mejía, C. Bueno, P.J. Real, **P. Menendez***. Intrahepatic transplantation of Cord Blood CD34+ cells into newborn NOD/SCID-IL2R γ ^{null} mice allows efficient multi-organ and multi-lineage hematopoietic engraftment without accessory cells. **Clin Immunol** 2012; 145: 89-91.

MC. Chillón, M. Gómez-Casares, CE. López-Jorge, C. Rodríguez-Medina, A. Molines, ME. Sarasquete, M. Alcoceba, JD. González-San Miguel, C. Bueno, R. Montes, F. Ramos, JN. Rodríguez, P. Giraldo, M. Ramírez, R. García-Delgado, JL. Fuster, M. González-Díaz and **P. Menéndez***. Prognostic significance

of FLT3 mutational status and expression levels in MLL-AF4 and MLL-germline Acute Lymphoblastic Leukemia. **Leukemia** 2012;26:2360-2366.

P. Muñoz, M. Toscano, P. Real, K. Benabdellah, M Cobo, C. Bueno, V. Ramos-Mejía, **P. Menendez**, P. Anderson & F. Martín. "Specific marking of hESCs-derived hematopoietic lineage by WAS-promoter driven lentiviral vectors". **PLoS ONE** 2012; 7: e39091.

M. Rosu-Myles, Y-M. She, J. Fair, G. Muradia, J. Mehic, **P. Menendez**, S. Prasad, T.D. Cyr. "Identification of a Candidate Proteomic Signature to Discriminate Multipotent and Non-Multipotent Stromal Cells" **PLoS ONE** 2012;7: e38954.

V. Ramos-Mejía, Rosa Montes, Clara Bueno, Verónica Ayllón, Pedro J Real, René Rodriguez & **Pablo Menéndez***. "Residual expression of ectopic reprogramming factors prevents differentiation of human induced Pluripotent Stem Cells generated from fibroblasts and cord blood-CD34+ cells" **PLoS ONE** 2012; 7: e35824.

P.J. Real, G. Ligeró, I. Gutiérrez-Aranda, C. Bueno, V. Ramos-Mejía, V. Ayllón, L. Sánchez, M. Lako & **P. Menéndez***. SCL/TAL1 expression regulates hematopoietic specification from hESCs. **Mol Ther.** 2012; 20:1443-1453.

L. Sánchez, I. Gutiérrez-Aranda, Gertrudis Ligeró, Verónica Ayllón, Pedro J Real, Verónica Ramos-Mejía, Clara Bueno & **Pablo Menéndez***. "Maintenance of hESCs in media conditioned by human mesenchymal stem cells obviates the requirement of exogenous bFGF supplementation" **Tissue Engineering.** 2012;18: 387-396.

C. Bueno*, R. Montes, L. Sánchez, G. Ligeró, I. Gutiérrez-Aranda, V. Ramos-Mejía, P. Real, A. Fernandez, MF. Fraga, I. Moreno, D. Burks, MC. Plaza, J.C. Rodríguez-Manzanares, **P. Menéndez***. "A human ESC model for MLL-AF4 reveals an impaired early hemato-endothelial specification" **Cell Res** 2012. 22: 986-1002.

[received the following comment: Cell Res 2012;22:948/selected for Journal Cover June 2012 Issue]

V. Ramos-Mejía, M. Fraga and **P. Menéndez***. "Induced PSCs from cancer cells: challenges and opportunities". **Trends in Mol Med** 2012;18: 245-248.

M. Martín & **P. Menendez***. "Biological impact of human embryonic stem cells". **Adv Exp Med Biol.** 2012; 741: 217-230.

R Rodriguez, J García-Castro, C Trigueros, M García-Arrenz & **P Menendez***. Multipotent mesenchymal stromal cells: clinical applications and cancer modeling. **Adv Exp Med Biol.** 2012; 741: 187-205.

V. Calvanese, A. Fernández, R. G. Urdinguio, B. Suárez, C. Mangas, V. Pérez-García, C. Bueno, R. Montes, V. Ramos-Mejía, P. Martínez, C. Ferrero, Y. Assenov, C. Bock, **P. Menéndez**, A. Carrera, C. López-Larrea & M.Fraga. "A promoter DNA demethylation landscape of hematopoietic differentiation. **Nucleid Acid Res** 2012; 40: 116-131.

C. Romero-López, A. Barroso-delJesús, **P. Menéndez** & A. Berzal. "Analysis of mRNA abundance and stability by ribonuclease protection assay". **Methods Mol Biol.** 2012; 809: 491-503.

V. Ramos-Mejía, V. Ayllón, A.F. Fernández, G. Ligeró, L. Sánchez, C. Bueno, P. J. Real, M.F. Fraga, **P. Menéndez***. Maintenance of hESCs in mesenchymal stem cell-conditioned media augments hematopoietic specification. **Stem Cells Dev** 2012; 21:1549-1558.

V. Ramos-Mejía, C. Bueno, M. Roldán, L. Sánchez, G. Ligeró, **P. Menéndez***, M. Martín. The adaptation of human ESCs to different culture conditions relies on mitochondrial response. **Stem Cells Dev** 2012; 21:1145-1155.

R. Rodríguez, R. Rubio, **P. Menéndez***. "Modelling Sarcomagenesis using Mesenchymal Stem Cells" **Cell Res** 2012; 22:62-77.

J.A Marchal, M. Picón, M. Perán, C. Bueno, M. Jiménez, E. Carrillo, H. Boulaiz, N. Rodríguez, P. Álvarez, **Pablo Menéndez**, E. de Teresa, A. Aránega. "Purification and long-term culture multipotent endothelial-like cells with potential cardiovascular regenerative capacity". **Stem Cell Dev** 2012; 21: 562-574.

2011

S. Yung, M. Ledran, I. Moreno-Gimeno, A. Conesa, D. Montaner, J. Dopazo, N.J. Slater, L. Marenah, P. Real, I. Paraskevopoulou, V. Bisbal, D. Burks, M. Santibanez, R. Moreno, J. Mountford, **P Menendez**, L. Armstrong, M. Lako. "Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human ESCs". **Hum Mol Genet**; 2011; 20: 4932-4946.

P. Menéndez* and C. Bueno. Expression of NG2 antigen in MLL-rearranged leukemias: how complex does it get?. **Leuk Res** 2011; 35: 989-990.

R. Montes, V. Ayllón, I. Gutiérrez-Aranda, I. Prat, M.C. Hernández-Lamas, L. Ponce, S. Bresolin, G. te Kronnie, M. Greaves, C. Bueno*, **P. Menéndez***. "Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and progenitor potential but is not sufficient for leukomogenesis". **Blood** 2011;117:4746-4758.

C. Bueno, R. Montes, P. Catalina, R. Rodríguez, **P. Menéndez***. "Insights about the cellular origin and etiology of the infant pro-B Acute Lymphoblastic Leukemia with the MLL-AF4 rearrangements". **Leukemia** 2011; 25:400-410.

R. Rodríguez, R. Rubio, I. Gutierrez-Aranda, G. Melen, J. García-Castro & **P. Menéndez***. "Expression of the FUS-CHOP fusion protein coupled to p53 deficiency induces liposarcoma in fat-derived murine but not human Mesenchymal Stem Cells" **STEM CELLS** 2011; 29: 179-192.

A. Barroso, G. Lucena, L. Sánchez, I. Gutierrez-Aranda & **P. Menéndez***. "The Nodal inhibitor LEFTY is negatively regulated by the microRNA (miR)-302 in human ESCs". **FASEB J** 2011; 25:1497-1508.

L. Sánchez, I. Gutierrez-Aranda, G. Ligeró, R. Rubio, M. Muñoz, J.L. García-Pérez, V. Ramos-Mejía, P.J. Real, C. Bueno, M. Delgado, R. Rodríguez & **Pablo Menéndez***. "Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease" **STEM CELLS** 2011; 29: 251-262.

2010

V. Ramos-Mejía, L. Sánchez, I. Gutiérrez, G. Ligeró, J.L. Cortés, G. Melen, P. Real, C. Bueno & **Pablo Menéndez***. “Nodal/activin signalling predicts human pluripotent stem cell lines prone to differentiate towards the hematopoietic lineage” **Mol Ther** 2010;18:2173-2181.

V Ramos-Mejía, M. Muñoz-López, J.L García-Pérez & **Pablo Menéndez***. “iPSCs lines which do not silence the expression of the ectopic reprogramming factors may display enhanced propensity to genomic instability” **Cell Res** 2010; 20:1092-1095.

I. Gutierrez, L. Sanchez. G. Ligeró, C. Bueno, P. Real, A. Macía, M. Muñoz-López, V, Ramos-Majía, Jose. L. García-Pérez & **Pablo Menéndez***. “Human iPSCs develop teratoma more efficiently and faster than hESC regardless the site of injection”. **STEM CELLS** 2010; 28:1568-1570.

JL. García-Pérez, M. Morell, J. Scheys, D. Kulpa, S. Morell, C. Carter, G. Hammer, K. Collins, K. Sue O’Shea, **P. Menendez**, J.V.Moran. “Efficient and reversible epigenetic silencing of LINE-1 retrotransposition events in embryonic carcinoma cell lines”. **Nature** 2010; 466: 769-773.

M.A. Blanco-Gelaz, B. Suárez, L. Sánchez, G. Ligeró, H. Moore, **P. Menéndez** & C. López-Larrea. “Reticulum stress signals in defined Human Embryonic Stem Cell lines and culture conditions”. **Stem Cell Rev.** 2010; 6: 462-472.

R. Rubio, J. García-Castro, I. Gutierrez-Aranda, J. Paramio, M. Santos, **P. Menéndez***, R. Rodriguez. “p53 but not Rb deficiency induces in vitro transformation of MSCs and originates leiomyosarcoma in vivo.” **Cancer Res.** 2010; 70: 4185-4194.

C. Bueno, R. Montes, **P. Menendez***. “The ROCK inhibitor Y-27632 negatively affects the expansion/survival of both fresh and cryopreserved Cord Blood-derived CD34+ Hematopoietic Progenitor Cells”. **Stem Cell Rev.** 2010; 6: 215-223.

C. Bueno, R. Montes, T. Cueva, I. Gutierrez, **P. Menendez***. “Multilineage engraftment of the NOD/LtSz-scid IL2R γ ^{null} mouse strain by human CD34+ cells without previous irradiation or myeloablative conditioning”. **Cytotherapy.** 2010; 12: 45-49.

2009

P. Andrews, J. Arias, J. Auerbach, M. Alvarez, **P. Menendez**, A. Zapata, F Zeng & Q.Zhou. “Consensus Guidance for Banking and Supply of Human Embryonic Stem Cells Lines for Research Purposes. The International Cell Banking Initiative”. **Stem Cell Rev.** 2009; 5: 301-314.

P. Menendez*, P. Catalina, R. Rodriguez, G. Melen, C. Bueno, M. Arriero, F. García-Sánchez, A. Lassaleta, R. García-Sanz, J. García-Castro*. Bone Marrow Mesenchymal Stem Cells from infant MLL-AF4+ leukemia harbour and express the MLL-AF4 fusion gene. **J. Exp. Med.** 2010; 206: 3131-3141.

C. Bueno, P. Catalina, GJ Melen, RM. Montes, L. Sánchez, G. Ligeró, **P. Menéndez***. Etoposide Induces MLL Rearrangements and other chromosomal abnormalities in hESCs. **Carcinogenesis**. 2009. 30; 1628-1637.

P. Catalina, C. Elosúa, J.L. Cortés, A. Nieto, J.L. García-Pérez, **P. Menéndez**, P.E. Leone. Characterization of the chromosomal stability of human ESC lines. **LAJD**. 2009; 2: 5-9.

J.L. Cortés, L. Sanchez, G. Ligeró, I. Gutierrez, P. Catalina, C. Elosua, P. Leone, R. Montes, C. Bueno, V. Ramos-Mejía, I. Maleno, J.L. García-Pérez & **P. Menéndez***. "Mesenchymal stem cells facilitate the derivation of human embryonic stem cells from cryopreserved poor-quality embryos". **Human Rep**. 2009; 24:1844-1851.

R. Montes, G. Ligeró, L. Sanchez, P. Catalina, T Cueva, G. Melen, A. Nieto, R. Rubio, J. García-Castro, C. Bueno & **P. Menéndez***. "Feeder-free xeno-free maintenance of hESCs in mesenchymal stem cell-conditioned media: distinct requirements for TGF- β and IGF-II". **Cell Res**. 2009. 19:698-709.

Jose Luis Cortés, **Pablo Menéndez***. Reproductive medicine meets hESC research: need to adjust the regulatory framework to actual expectations about hESC research and its potential detrimental consequences". **Fertility and Sterility**. 2009;91:1417-1419.

R. Rodriguez, M. Masip, R. Rubio, P. Catalina, A. Nieto, T Cueva, M. Arriero, N. San Martín, E. Cueva, D. Balomenos, **P. Menéndez** & J. García-Castro. "Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells". **Neoplasia**. 2009;11:397-407.

2008

A. Barroso, G. Lucena & **P. Menéndez***. "The miR302-367 cluster as a potential stemness regulator in ESCs". **Cell Cycle**. 2009;8:394-398.

P. Catalina, R. Montes, A. Nieto, G. Ligeró, L. Sanchez, M. Jara, A. Orfao, JC. Cigudosa, O. Hovatta, M. Greaves, C. Bueno & **P. Menéndez***. "Scientific and clinical opportunity for modelling infant/childhood leukaemia using genetically stable human embryonic stem cells". **Leuk Res** 2009;33:980-990.

P. Catalina, R. Montes, G. Ligeró, L. Sánchez, T. de la Cueva, C. Bueno, P. Leone & **P. Menéndez***. "Human ESCs predisposition to karyotypic instability: Is a matter of cell culture adaptation or differential vulnerability among hESC lines due to inherent properties?". **Mol Cancer** 2008;7:76-81.

V. Calvanese, A. Hornillo, K. Hmadcha, B. Suarez, A. Fernandez, E. Lara, S. Casado, **P. Menéndez**, C. Bueno, J. García, R. Rubio, P. Lapuncina, M. Alaminos, L. Borguense, N. Harrison, O. Brustle, C. Lopez-Larrea, P. Andrews, B. Soria, M. Esteller, M. Fraga. "Cancer genes hypermethylated in human embryonic stem cells". **PLOS One** 2008; 3: 3294.

J. García-Castro, C. Trigueros, J. Madrenas, JA. Pérez-Simón, R. Rodriguez & **P. Menéndez***. Mesenchymal Stem Cells and their potential applications in cell replacement therapies, immune tolerance and disease modelling". **J Cell Mol Med**. 2008;12:2552-2565.

A. Barroso, C. Romero, G. Lucena, G. Melen, G. Ligeró, L. Sánchez, A. Berzal, **P. Menendez***. Embryonic Specific miRNA302-367 cluster: Gene Structure and Functional Characterization of the Proximal Core Promoter. **Mol Cell Biol.** 2008; 28: 6609-6619.

F. Shojaei & **P. Menéndez***. "Molecular Profiling of Candidate Human Hematopoietic Stem Cells derived from hESCs" **Exp Hematol** 2008; 36: 1442-1454.

J Ji. K. Vijayaragavan, M. Bosse, **P. Menendez**, K. Weisel & M. Bhatia. OP9 Stroma Augments Survival of Hematopoietic Precursors and Progenitors During Hematopoietic Differentiation from Human ESCs. **STEM CELLS** 2008; 26:2485-2495.

C. Bueno, R. Montes, L. Martín, I. Prat, MC. Hernández, A. Orfao, **P. Menendez***. NG2 antigen is expressed in CD34+ HPCs and plasmacytoid dendritic cell-precursors: Is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered? **Leukemia** 2008. 22;1475-1478.

P. Menendez*. Making business out of patients?. **Blood** 2008; 112:1543.

P. Menendez* Electron Microscopy Reveals the Presence of Viruses in Mouse Embryonic Fibroblasts but neither in Human Mesenchymal Cells nor HEFs used for hESC maintenance: Towards an Implementation of Microbiological Quality Assurance Program in Stem Cell Banks. **Cloning and Stem Cells.** 2008;10:65-74.

JL Cortés, LSánchez, P Catalina, F Cobo, C.Bueno, A. Marínez-Ramirez, A. Barroso, C. Cabrera, G. Ligeró, R. Montes, R. Rubio, Ana Nieto & **Pablo Menéndez***. "Development of a two-step laser-based approach to enhance the efficiency of ESC establishment from good and poor-quality embryos". **Stem Cells and Dev.** 2008;17:255-268.

Clara Bueno, Rosa Montes, Javier García-Castro, Mel Greaves, **Pablo Menéndez***. "Human Embryonic Stem Cells: A Potential System For Modeling Infant Leukemia Harboring MLL-AF4 Fusion Gene". **Drug Discovery Today: Dis Models** 2008; 4:53-60.

2007

Clara Bueno, Luiz F. Lopes, Mel Greaves, **Pablo Menendez***. "Towards the development of a novel NOD/SCID-based in vivo strategy to model MGUS and MM pathogenesis" **Exp Hematology.** 2007;35:1477-1478.

C. Bueno, L.F. Lopes, **P Menendez***. "Bone marrow stromal cells-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32)".**Blood Cell Mol Dis.** 2007; 39: 366-368.

S. Bendall, M. Stewart, **Pablo Menendez**, D. George, K. Vijayaragavan, T. Werbowetski, V. Ramos, J. Yang, M. Bosse, G. Lajoie and M. Bhatia. "IGF and FGF cooperatively establish the regulatory stem niche of pluripotent human cells".**Nature.**2007;448:1015-102.

JL. Cortés, G. Antiñolo, L. Martinez, F. Cobo, A. Barnie, A. Zapata, **P. Menendez***. "Spanish Stem Cell Bank interviews examine the couple's interest in donating surplus human IVF embryos more than 3 years old for stem cell research" **Cell Stem Cell** 2007;1:17-20.

P. Catalina, F. Cobo, JL. Cortés, A. Nieto, C. Cabrera, R. Montes, A. Concha and **P. Menéndez***. "Convencional and molecular cytogenetic diagnostic methods in stem cell research: A concise review. **Cell Biol Int** 2007;31:861-869.

JL Cortes, F.Cobo, P. Catalina, A. Nieto, C. Cabrera, R. Montes, A Barnie, A. Concha & **P.Menendez***. "Evaluation of the laser technique method to isolate the inner cell mass of murine blastocysts." **Biotech and Biochem** 2007;46:205-209.

1998-2006 (as a trainee)

P.Menendez*, C. Bueno & L.Wang. "Human Embryonic Stem Cells: A Journey Beyond cell Replacement Strategies". **Cytotherapy** 2006;8:530-541.

M Stewart, M Bossé, K Chadwick, **P Menendez**, S Bendall & M Bhatia. "Clonal isolation of hESCs reveals heterogeneity within the pluripotent stem cell compartment". **Nature Methods** 2006; 3, 807-815.

P.Menendez*, L. Wang, C. Cerdan & M. Bhatia. "Retroviral transduction of hematopoietic progenitors derived from hESC". **Methods Mol Biol** 2006;331:201-220.

L. Wang, C. Cerdan, **P. Menendez** & M Bhatia. "Derivation and characterization of hematopoietic cells derived from hES cells". **Methods Mol Biol** 2006;331:179-200.

P.Menendez, C. Bueno, L.Wang & M.Bhatia. "Human embryonic stem cells: Potential tool towards achieving immunetolerance?". **Stem Cell Rev** 2005;1:151-158.

K.Levac, **P.Menendez**, L.Gallacher & M.Bhatia. "Intra-bone marrow transplantation facilitates pauciclonal human hematopoietic repopulation of NOD/SCID B2m^{-/-} mice". **Exp Hematol** 2005;33:1417-1426.

L.Wang, **P.Menendez**, C.Cerdan, M.Bhatia. "Human embryonic stem cells as a new source of hematopoietic cells". **Exp. Hematol** 2005;33:987-996.

P.Menendez, L.Wang & M.Bhatia. "Genetic manipulation of human embryonic stem cells: a powerful approach for studies in human development and potential therapeutic applications". **Current Gene Therapy** 2005; 5:375-385.

L.Wang, L. Li, **P. Menendez**, C. Cerdan & M. Bhatia. "Human embryonic stem cells maintained in the absence of mouse embryonic fibroblasts or conditioned media are capable of hematopoietic development" **Blood** 2005;105:4598-4603.

L. Wang*, **P. Menendez***, F.Shojaei, F. Mazurier, J. Dick, K. Levac, & M. Bhatia. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HoxB4 expression. **J. Exp. Med** 2005;201:1603-1615. ***First author equal contribution.**

P. Menendez, L. Wang, K. Chadwick, L. Li & M. Bhatia. "Retroviral transduction of hematopoietic progenitor cells differentiated from human embryonic stem cells derived CD45^{neg}PFV precursors". **Mol Ther** 2004;10:1109-20. [This article received the following comment: Mol Ther 2004; 10: 974].

L.Wang, L.Li, F.Shojaei, **P.Menendez**, T.Martin, A.Rouleau, M.Bhatia. "Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties". **Immunity** 2004; 21:31-41.

P.Menéndez, A.Vargas, C.Bueno, S.Barrera, A.Lopez, S.Roa, J.Almeida, JF. San-Miguel, A.Orfao. "Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation". **Leukemia**. 2004; 18:491-498.

K. Chadwick, L. Wang, L. Li, **P. Menéndez**, B. Murdoch, A. Rouleau, M. Bhatia. Cytokines and BMP-4 differentiate human embryonic stem cells towards the hematopoietic lineage. **Blood**. 2003; 102: 906-915.

F. Prósper, C. Solá, J. Hornedo, C. Arbona, **P. Menéndez**, A. Orfao, A. Luch, H. Cortés-Funes, JJ. López, J. García-Conde. "Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy". **Leukemia**. 2003; 17: 437-441.

P.Menéndez, MD.Caballero, F.Prosper, M.C. Cañizo, J.A. Pérez-Simón, MV.Mateos, MJ.Nieto, M.Corrál, M.Romero, J.García-Conde, M.A.Montalbán, J.F. San-Miguel, A.Orfao. "The composition of the leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen". **Transfusion**. 2002; 42:1159-1172.

P. Menéndez, JA. Pérez-Simón, MV. Mateos, MD. Caballero, M. Gonzalez, JF. San-Miguel, A. Orfao. Influence of the different CD34⁺ and CD34⁻ cell subsets infused on non-myeloablative allogeneic peripheral blood transplantation from HLA-identical sibling donors. **Br. J.Haematol**. 2002;119: 135-143.

GE. Benito, ML. Sánchez, J. del Pino, JJ. Calvo, **P. Menéndez**, MA. García-Marcos, P. Osdoby, A. Orfao. "A new method for the immunophenotypic characterization of bone-derived human osteoclasts". **Cytometry**. 2002; 50: 261-266.

P. Menéndez, F. Prósper, C. Bueno, C. Arbona, JF. San-Miguel, J. García-Conde, C. Solá, J. Hornedo, H. Cortés-Funes and A. Orfao. "Sequential analysis of CD34⁺ and CD34⁻ cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilised with SCF plus G-CSF and cyclophosphamide". **Leukemia**. 2001; 15: 430-439.

P. Menéndez, MC. Del Cañizo and A. Orfao. "Immunophenotypic characteristics of PB-mobilised CD34⁺ hematopoietic progenitor cells". **JBRHA**. (Review). 2001; 15: 53-61.

JL. Arroyo, MA. García-Marcos, A. López. **P. Menéndez**, MD. Tabernero, LI. Sanchez-Abarca, JF. San-Miguel and A. Orfao. "Evaluation of the CD61-immunoPLT method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion-decision-making process". **Transfusion**. 2001; 41:1212-1216.

J.W. Gratama, **P. Menéndez**, J. Kraan and A. Orfao. "Loss of CD34+ hematopoietic progenitor cells due to washing can be reduced by use of fixative free rather than fixative-containing erythrocyte lysing reagents". **J of Immunol Methods**. 2000; 239: 13-23.

J Kappelmayer, JW Gratama, E Karaszi, **P Menéndez**, J. Ciudad, R. Rivas and A. Orfao. "Flow cytometry detection of intracellular myeloperoxidase, CD3 and CD79a: interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols". **J Immunol Methods**. 2000; 242: 53-65

D. Barnett, V. Granger, J. Kraan, L. Whitby, J.T. Reilly, S. Papa and J. Gratama for and on behalf of the CD34 task force of the EWGCCA, **P. Menendez** (See appendix). "Reduction of intra- and inter-laboratory variation in CD34+ stem cell enumeration by the use of stable test material, standard protocols and targeted training". **Br.J. Haematology**. 2000; 108: 784-792.

P. Menéndez, O. Redondo, A. Rodriguez, MC. López-Berges, G. Ercilla, A. López, A. Durán, J. Almeida, JA. Pérez-Simón, JF. San Miguel, J.W. Gratama, A. Orfao. "Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells". **Cytometry**. 1998; 34: 264-271.

National peer-review publications:

Orfao, **P. Menéndez**, MC. López-Berges, JA. Pérez-Simón, A. Martín, MC. Del Cañizo, MD. Caballero, G. Ercilla, J. Ciudad, M. Corral, JF. San Miguel. "Cuestiones actuales sobre células progenitoras hematopoyéticas CD34". **Sangre**. 1999; 44: 30-35.

JL.Cortés, G. Ligeró, A. Sánchez, A. Nieto, C. Bueno, R. Montes & **P. Menéndez***. "Morphological Assessment of Human Oocytes, early Embryos and Blastocysts proposed by ASEBIR" **ASEBIR** 2008; 14: 6-13.

P. Menéndez*, C. Bueno, R. Montes, G. Ligeró, L. Sánchez, R. Rubio, R. Rodríguez, M. Masip, J. García-Castro. "Células Madre y Cáncer: ¿Cuál es la célula diana sensible a una transformación en LLA pro-B MLL-AF4+?" **Methods Find Exp Clin Pharmacol**. 2008; 30:25-33.

J.García-Castro, P. Catalina, G. Melen, R. Rodríguez, C. Bueno, M. Arriero. A. Lassaleta & **P. Menendez***. ¿Es el estroma medular parte del clon leucémico en la LLA pro-B MLL-AF4?. **Methods Find Exp Clin Pharmacol**. 2009; 31:17-20.

C. Bueno, R. Montes, P. Catalina, R. Rodríguez, G. Melen, V. Ramos, P. Real, M. Arriero, A. Lassaleta, J. García-Castro, R. García-Sanz, L. Martín, A. Orfao, **P. Menéndez***. "Etiología y origen celular de la Linfoblástica Aguda B del lactante con reordenamiento MLL-AF4". **Haematologica** 2010; 95:404-409.

P. Menéndez, M. Santiago, M. Ayuso, MC Cañizo, J.A. Pérez-Simón, M.D. Caballero, F. Prósper, M. Romero, J. García-Conde, MA. Montalbán, J.F San-Miguel, A. Orfao. "The effect of mobilization regimens on the quantity and quality of CD34+ HSC harvested in leukapheresis products" **Methods Find Exp Clin Pharmacol**. 2001; 23: 9-15.

Opinion publications:

P. Menéndez. Public Biobanking: A way to avoid making profit out of patients. Public Service Review: European Union. 2010. Issue 20:1-2.

C. Ockleford, **P. Menendez** et al on behalf EFSA Panel on Product Protection. Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia. **EFSA J** 2017;15:3.

XIII.- BOOK CHAPTERS

Authors: Miguel Martín & Pablo **Menendez***
Title: El impacto biológico de las células madre embrionarias
Book Title: **Frontiers in Clinical Investigation**
Editorial: McGraw-Hill/Interamericana 2008

Authors: Javier García-Castro, Clara Bueno, Jose L. Cortés, Ana Nieto, **Pablo Menendez***
Title: Células Madre y Terapia Celular
Book Title: **Biotecnology and Health**
Editorial: Editorial Ephemera, Madrid 2007

Authors: **Pablo Menéndez***, Clara Bueno and Mel Greaves
Title: Células Madre: Hipotesis científica como base en el correcto abordaje de un proyecto biomédico.
Book Title: **Medicina Regenerativa**
Editorial: Ediciones Poliedro 2007

XIV.- INVITED LECTURES (only oral communications)

National: 91
International: 57

"More detailed information provided upon request"

XV.- PATENTS:

Inventors: Nestor Tirado, Diego Sánchez, Victor Diaz, MJ Mansilla, Alba Garcia, **Pablo Menéndez**
Title: Humanized CCR9 targeting moiety for the treatment of CCR9+ cancer.
Reference Number: PCT/EP2024/053734 Country: España Date: February 14th 2024
Property/University: Institute Josep Carreras - **Licensed to OneChain Immunotherapeutics SL**

Inventors: Victor Díaz, Laura García, Diego Sánchez, **Pablo Menéndez**
Title: Humanized CD1a targeting moiety for the treatment of CD1a-positive cancer.
Reference Number: **EP22382174.5** Country: España Date: February 28th 2022
Property/University: Institute Josep Carreras - **Licensed to OneChain Immunotherapeutics SL**

Inventors: Samanta Zanetti, Talía Velasco, Pablo Engel, **Pablo Menéndez**
Title: CD22 targeting-moiety for the treatment of B-ALL
Reference Number: **WO2020/165350** Country: España Date: March 4th 2020

Property/University: Institute Josep Carreras - **Licensed to OneChain Immunotherapeutics SL**

Inventors: Raul Torres, **Pablo Menéndez**, Sandra Rodríguez-Perales

Title: Gene editing based cancer treatment

Number: **PCT/EP2019/078408** Country: España Date: Date: October 14th 2019

Property/Company/University: CNIO-Institute Josep Carreras

Inventors: Diego Sánchez, Heleia Roca, Francisco Gutiérrez, Clara Bueno, **Pablo Menéndez**

Title: CAR T-cells for the treatment of CD1a+ cancer

Reference Number: **PCT/EP2020/053769 - WO2020/165350**

Country: España Date: February 14th 2019

Property/University: Institute Josep Carreras - **Licensed to OneChain Immunotherapeutics SL**

Inventors: Cristina Prieto, Heleia Roca, Belén López-Millán, Clara Bueno, **Pablo Menéndez**

Title: NG2 antigen as a therapeutic target in MLL-rearranged acute leukemia

Reference Number: **EP17382551.4** Country: España Date: September 4th 2017

International Extension: PCT/EP2018/071177 September 4th 2018

Property/Company/University: Institute Josep Carreras

Inventors: Pedro Real, Miguel Toscano, Francisco Martín, Clara Bueno, Verónica Ayllón, Verónica Ramos, Oscar Navarro, **Pablo Menéndez**

Title: Method for generation of human megakaryocytes and platelets

Reference Number: **P201331568** Country: España Date: October 24th 2013

Property/Company/University: Fundación Progreso y Salud

Inventors: **Pablo Menéndez**, René Rodríguez

Title: Cells, cell lines and a human model for mixoid liposarcoma for the determination of novel therapeutic agents.

Reference Number: **P201232078** Country: España Date: December 31th 2012

Property/Company/University: Fundación Progreso y Salud

Inventors: **Pablo Menéndez**, René Rodríguez, Ruth Rubio

Title: Progenitores osteogénicos derivados de células madre mesenquimales y depleccionados para Rb y p53 generadores de osteosarcoma.

Reference Number: **P2012030999** Country: España Date: June 27th 2012

Property/Company/University: Fundación Progreso y Salud

Inventors: **Pablo Menéndez**, Mario Delgado, René Rodríguez, Ruth Rubio, Gertrudis Ligeró, Laura Sánchez, Iván Gutierrez-Aranda, Verónica Ramos, Clara Bueno

Title: Procedimiento para la obtención de células madre mesenquimales para uso biomédico.

Reference Number: **P201030645** Country: España Date: April 30th 2010

Property/Company/University: Fundación Progreso y Salud

Inventors: **Pablo Menéndez**, Verónica Ramos, Clara Bueno, Pedro Real, Gertrudis Ligeró, Laura Sánchez

Title: Uso de un medio de cultivo condicionado por células madre mesenquimales para la diferenciación de células madre pluripotentes humanas

Reference Number: **P0201030512** Country: España Date: April 8th 2010
Property/Company/University: Fundación Progreso y Salud

Inventors: **Pablo Menéndez**, René Rodriguez and Ruth Rubio
Title: Leyomiosarcoma-initiating Mesenchymal Stem Cell Lines depleted of p53 and Rb
Reference Number: **P0201030217** Country: España Date: February 16th 2010
Property/Company/University: Fundación Progreso y Salud

Inventors: **Pablo Menéndez**, René Rodriguez, Javier García-Castro & Ruth Rubio
Title: Célula madre multipotencial aislada procedente de un humano, modificada genéticamente y método para producirla
Reference Number: **P200930426** Country: España Date: 2009
Property/Company/University: Fundación Progreso y Salud

Inventors: Javier García-Castro, Teresa de la Cueva, René Rodriguez, Ruth Rubio, Manuel Masip, **Pablo Menéndez**, Mar Arriero & Agustín Zapata
Title: Uso de células madre mesenquimales en la preparación de una composición para terapia celular.
Reference Number: **P200930033** Country: España Date: April 2nd 2009
Property/Company/University: Fundación Progreso y Salud

Inventors: **Pablo Menéndez** & Alicia Barroso del Jesús
Title: Stem cell-specific promoter
Reference Number: **P200800957** Country: España Date: 2008
Property/Company/University: Fundación Progreso y Salud

Inventors: **Pablo Menéndez** & J.L. Cortés
Title: Procedure for the isolation of the inner cell mass from mammalian blastocysts
Reference Number: **P200701625** Country: España Date: June 1st 2007
International Extension: PCT/ES2008/000377 / May 23rd 2008
Property/Company/University: Fundación Progreso y Salud

XVI.-ENTREPRENEUR ACTIVITIES

Founder of **OneChain Therapeutics S.L.** "Spin-off" company of Josep Carreras Leukemia Institute
May 2020. CIF: B19510346

Co-Founder of **Tanglegen Inc.** "Spin-off" company of University of Granada.
December 2012. CIF: B19510346

XVII.- EXPERIENCE IN ORGANIZATION OF SCIENTIFIC-TECHNOLOGIC ACTIVITIES:

- 2016 ICREA Conference Award
Tumor heterogeneity and cancer evolution.
Barcelona, Spain.
- 2012 EuroStemCell Outreach Activity

- 27th April. Barcelona. Spain.
2010 Spain-UK Bilateral Stem Cell Workshop.
March 24th-25th. London, UK. Organizer and Chair.
2009 V Meeting of the Spanish Society of Cell & Gene Therapy.
October 1st-3rd. Granada. Spain. Organizer.
2000 VI Joint Meeting of the Iberian Society of Flow Cytometry.
July 1st-4th. University of Salamanca. Spain. Organizer.

XVIII.- SCIENTIFIC AND EDITORIAL ADVISORY BOARDS:

- 2024-2028 Board of Directors Member, International Society Experimental Hematology (ISEH).
2022-present Scientific member of the Spanish Network for Relapse pediatric leukemia.
2020-present Invited member of the International-BFM task force on pediatric leukemia.
2017-2021 Nominated as Member of the Management Committee of the e-COST action
“LEukaemia GENE Discovery by data sharing, mining and collaboration”
2015-2018 *Ad Hoc* Advisor for the European Food and Safety Authority (EFSA)
Mandate: Properties of PPP's linked to childhood leukemia
2011-2015 Vocal of the Spanish Association of Gene and Cell Therapy
2009-2013 Member of the Scientific Advisory Board of InbioBank. San Sebastian.
2007-2018 Member of the Scientific Advisory Board of the EU hESC registry
2006-2018 Vocal of The Spanish Stem Cell Bank Steering Committee (ISCIII)

XIX.- DOCTORAL/MASTER THESIS:

1.-CD123-directed CARs fro AML: efficacy and myeloablative effects

PhD candidate: Matteo L Baroni. 17th July 2020

2.-Cell-of-origin and clinical prognostic markers in infant B-ALL by genome-wide analysis.

PhD candidate: Antonio Agraz Doblás. 8th November 2018.

3.-Insights into the pathogenesis of infant pro-B Acute Lymphoblastic Leukemia with t(4;11).

PhD candidate: Cristina Prieto Fernández. 31th March 2017.

Awarded “Miguelín” prize by “Apadrina la Ciencia” for Best 2017 Thesis on pediatric cancer.

4.-Mitochondria and stem cell function: from somatic cells to disease modelling.

PhD candidate: Damià Romero-Moya. 16th January 2017.

5.-Contribution of RUNX1 isoforms to the regulation of hematopoietic specification of hESCs.

PhD candidate: Oscar Montero-Navarro. 11th July 2016.

6.-In vitro impact of MLL-AF4 fusion in Fetal Liver c-kit+ HSPCs.

Master Student: Pamela Acha. 17th July 2015

7.-Advances in the etiology, pathogenesis and cell of origin of the newborn pro-B Acute Lymphoblastic Leukemia with t(4;11) MLL-AF4+

PhD candidate: Purificación Catalina Carmona. 5th December 2013

8.-Modelling Sarcomagenesis using MSCs: a role for p53 and Rb

PhD candidate: Ruth Rubio Amador. 10th June 2013

9.-Development of a human model for childhood pro-B Acute Lymphoblastic Leukemia with t(4;11) MLL-AF4+ based on hESCs and cord blood-derived CD34+ HSCs.

PhD candidate: Rosa María Montes. 10th May 2013

10.-RUNX1 isoform c regulates the hematopoietic specification from hESCs.

Master Student: Oscar Montero-Navarro. 21th September 2012.

11.-Role of p53 and Rb in mesenchymal stem cell transformation.

PhD candidate: Ruth Rubio Amador. 05th October 2009.

12.-Ethical and legislative aspects and optimization of the methodology for hESC derivation.

PhD candidate: Jose Luis Cortes. 16th April 2009.

XX.- MENTORSHIP and LEADERSHIP:

I have contributed to the career development of 20 research fellows. Ten of them have been appointed as (junior) Principal Investigators in other institutions:

- Jose Luis García Pérez – University of Edinburgh, Scotland.
- Clara Bueno – IJC. Barcelona, Spain.
- Pedro Real – University of Granada, Spain.
- René Rodríguez – IUOPA, Oviedo, Spain.
- Alicia Barroso – IPBLN, Granada. Spain.
- Alessandra Giorgetti - CMRB, Barcelona. Spain.
- Alejandra Sanjuan – La Fé Hospital. Valencia. Spain.
- Verónica Ramos-Mejía – GENyO, Granada. Spain.
- Diego Sánchez-Martínez – CIBA, Zaragoza, Spain.
- Paolo Petazzi – Integra Tx, Barcelona, Spain.

XXI.- AD HOC PUBLICATIONS PEER-REVIEWER:

I have acted as *ad hoc* peer-reviewer by invitation for the following Journals:

Nature Rev Cancer, Cancer Cell, Nat Protocols, Nature Genet, Nat Comm, Cell Rep, PNAS, Blood, Science Signalling, Science Advances, Cell Res, J Cell Sci, Clinic Cancer Res, Cancer Res, Leukemia, Stem Cells, Stem Cell Reports, PLoS ONE, Cell Mol Biol, Stem Cells & Dev, Genes Chrom & Cancer, Tissue Eng, J Mol Cell Med, FEBS Lett, Haematologica, Br J Hematol, Eur J Cancer, Cloning Stem Cells, Human Reproduction, Cytotherapy, Stem Cell Res.

XXII.- AD HOC GRANTS PEER-REVIEWER:

I have acted as a peer-reviewer/evaluator upon invitation for the following Funding Institutions:

- Paneles ANEP (AECC, Juan de la Cierva, Sara Borrell, FPU, plan nacional cáncer e inmunoterapia).
- Italian Ministry for Education, University and Research.
- Swiss Cancer League.
- Austrian Science Fund (FWF).
- Swiss National Science Foundation.
- Biotechnological and Biological Science Research Council. UK.
- Cancer Research UK
- Kay Kendall Leukaemia Fund. UK.
- Leukemia Research Fund. UK.
- Bloodwise Fund. UK
- Heart Research UK.
- Netherlands Organisation for Scientific Research (NWO).
- French National Cancer Institute (INCa)
- French Agence Nationale de Recherche. Stem Cell Biology and Hemato-oncology.
- Foundation for Polish Science. Cancer and stem cell biology.
- Comisión de Medicina Humana y Salud Pública de ANPCYT, Ministerio de Ciencia de Argentina.
- Instituto de Ciencia y Tecnología de Mexico.
- FIS-ISCI (Health Institute Carlos III).
- MICINN (Spanish Ministry on Science and Innovation).
- Andalusian Scientific Committee for evaluation of stem cell projects. Spain.
- Programa Nacional de Formación de RRHH de Investigación, MINECO. Spain.



Signed: Dr. Pablo Menendez

I am solely responsible for the accuracy and veracity of the contents here disclosed. All information here disclosed may be proved upon request.